1 0001711786 false Q3 --12-31 false 0001711786 2026-07-01 2026-09-30 0001711786 us-gaap:SubsequentEventMember 2026-10-01 2026-10-31 0001711786 2026-01-01 2026-09-30 0001711786 2025-12-31 0001711786 2026-09-30 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2026-09-30 0001711786 rkto:BiopharmaceuticalSegmentMember 2025-12-31 0001711786 rkto:BiopharmaceuticalSegmentMember 2026-09-30 0001711786 2025-01-01 2025-09-30 0001711786 rkto:BiopharmaceuticalSegmentMember 2025-01-01 2025-09-30 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2026-01-01 2026-09-30 0001711786 rkto:BiopharmaceuticalSegmentMember 2026-01-01 2026-09-30 0001711786 2025-07-01 2025-09-30 0001711786 rkto:BiopharmaceuticalSegmentMember 2025-07-01 2025-09-30 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2026-07-01 2026-09-30 0001711786 rkto:BiopharmaceuticalSegmentMember 2026-07-01 2026-09-30 0001711786 2025-03-01 2025-12-31 0001711786 2026-02-28 0001711786 us-gaap:GeneralAndAdministrativeExpense 2025-01-01 2025-09-30 0001711786 us-gaap:GeneralAndAdministrativeExpense 2026-01-01 2026-09-30 0001711786 us-gaap:GeneralAndAdministrativeExpense 2025-07-01 2025-09-30 0001711786 us-gaap:ProfessionalFees 2025-01-01 2025-09-30 0001711786 us-gaap:ProfessionalFees 2026-01-01 2026-09-30 0001711786 us-gaap:ProfessionalFees 2025-07-01 2025-09-30 0001711786 us-gaap:ProfessionalFees 2026-07-01 2026-09-30 0001711786 rkto:NonemployeeStockWarrantAwardsMember 2025-01-01 2025-09-30 0001711786 rkto:NonemployeeStockWarrantAwardsMember 2025-07-01 2025-09-30 0001711786 rkto:NonEmployeeRestrictedStockAwardsMember 2026-01-01 2026-09-30 0001711786 rkto:NonEmployeeRestrictedStockAwardsMember 2026-07-01 2026-09-30 0001711786 rkto:EmployeeRestrictedStockAwardMember 2025-01-01 2025-09-30 0001711786 rkto:EmployeeRestrictedStockAwardMember 2025-07-01 2025-09-30 0001711786 rkto:EmployeeStockOptionAwardsMember 2025-01-01 2025-09-30 0001711786 rkto:EmployeeStockOptionAwardsMember 2026-01-01 2026-09-30 0001711786 rkto:AboveSeventySixPointTwoFiveMember 2026-09-30 0001711786 rkto:AboveSeventySixPointTwoFiveMember 2026-01-01 2026-09-30 0001711786 rkto:FourteenPointSevenFiveToSeventySixPointTwoFiveMember 2026-09-30 0001711786 rkto:FourteenPointSevenFiveToSeventySixPointTwoFiveMember 2026-01-01 2026-09-30 0001711786 rkto:UpToTwoPointFiveNineMember 2026-09-30 0001711786 rkto:UpToTwoPointFiveNineMember 2026-01-01 2026-09-30 0001711786 2025-12-31 2025-12-31 0001711786 2025-09-30 0001711786 2026-05-31 2026-05-31 0001711786 2026-05-26 0001711786 2026-05-26 2026-05-26 0001711786 us-gaap:EmployeeStockOptionMember rkto:CommonStockWarrantsMember 2025-01-14 2025-01-14 0001711786 us-gaap:EmployeeStockOptionMember rkto:JanuaryTwoThousandAndTwentyThreeExistingWarrantsMember 2025-01-14 0001711786 us-gaap:EmployeeStockOptionMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-01-14 0001711786 us-gaap:EmployeeStockOptionMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-01-14 2025-01-14 0001711786 us-gaap:EmployeeStockOptionMember 2025-01-14 0001711786 us-gaap:EmployeeStockOptionMember 2025-01-14 2025-01-14 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2026-09-30 0001711786 srt:MaximumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2026-09-22 0001711786 srt:MinimumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2026-09-22 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2026-09-22 0001711786 srt:MaximumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-05-09 0001711786 srt:MinimumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-05-09 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2025-05-09 0001711786 srt:MaximumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2024-05-15 0001711786 srt:MinimumMember rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2024-05-15 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2024-05-15 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2023-06-02 0001711786 rkto:TwoThousandTwentyTwoEquityIncentivePlanMember 2022-03-24 0001711786 rkto:TwoThousandEighteenEquityIncentivePlanMember 2026-09-30 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2026-01-05 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2026-01-05 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2025-01-06 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2025-01-06 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2024-01-04 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2024-01-04 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2023-01-11 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2023-01-11 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2022-02-02 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember srt:BoardOfDirectorsChairmanMember 2022-02-02 0001711786 srt:MaximumMember rkto:TwoThousandEighteenEquityIncentivePlanMember 2021-06-24 0001711786 srt:MinimumMember rkto:TwoThousandEighteenEquityIncentivePlanMember 2021-06-24 0001711786 us-gaap:CommonStockMember rkto:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 0001711786 rkto:TwoThousandEighteenEquityIncentivePlanMember 2021-01-01 0001711786 us-gaap:CommonStockMember rkto:TwoThousandEighteenEquityIncentivePlanMember 2019-01-01 2019-01-01 0001711786 rkto:TwoThousandEighteenEquityIncentivePlanMember 2018-05-04 0001711786 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001711786 us-gaap:WarrantMember 2026-09-30 0001711786 us-gaap:WarrantMember 2025-12-31 2025-12-31 0001711786 us-gaap:WarrantMember 2025-12-31 0001711786 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-04 0001711786 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-04-02 0001711786 us-gaap:MeasurementInputOptionVolatilityMember 2025-06-04 0001711786 us-gaap:MeasurementInputOptionVolatilityMember 2026-04-02 0001711786 us-gaap:MeasurementInputExpectedTermMember 2025-06-04 0001711786 us-gaap:MeasurementInputExpectedTermMember srt:MaximumMember 2026-04-02 0001711786 us-gaap:MeasurementInputExpectedTermMember srt:MinimumMember 2026-04-02 0001711786 us-gaap:MeasurementInputExercisePriceMember 2025-06-04 0001711786 us-gaap:MeasurementInputExercisePriceMember srt:MaximumMember 2026-04-02 0001711786 us-gaap:MeasurementInputExercisePriceMember srt:MinimumMember 2026-04-02 0001711786 rkto:AprilPlacementAgentWarrantsMember 2026-04-02 0001711786 2026-04-02 0001711786 us-gaap:WarrantMember 2026-04-01 0001711786 2025-01-01 2025-06-30 0001711786 2025-04-01 2025-06-30 0001711786 2026-06-04 0001711786 us-gaap:WarrantMember 2026-06-04 0001711786 us-gaap:WarrantMember 2025-01-07 2025-01-07 0001711786 us-gaap:WarrantMember 2025-01-07 0001711786 us-gaap:WarrantMember 2024-03-27 0001711786 2026-06-10 0001711786 2026-06-10 2026-06-10 0001711786 us-gaap:CommonStockMember 2026-09-30 0001711786 us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001711786 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001711786 2026-05-14 0001711786 2026-05-14 2026-05-14 0001711786 2026-04-01 0001711786 2026-04-01 2026-04-01 0001711786 rkto:April2026WarrantsMember 2026-04-01 2026-04-01 0001711786 rkto:April2026WarrantsMember 2026-04-01 0001711786 us-gaap:CommonStockMember 2026-04-01 0001711786 us-gaap:CommonStockMember 2026-04-01 2026-04-01 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2026-07-01 2026-09-30 0001711786 rkto:ATMAgreementMember rkto:JanuaryTwoThousandAndTwentyThreeExistingWarrantsMember 2026-04-01 2026-06-30 0001711786 us-gaap:WarrantMember 2026-04-01 2026-06-30 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001711786 srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001711786 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2026-01-01 2026-09-30 0001711786 srt:ChiefExecutiveOfficerMember 2025-01-01 2025-09-30 0001711786 srt:ChiefExecutiveOfficerMember 2025-07-01 2025-09-30 0001711786 us-gaap:CommonStockMember srt:ChiefExecutiveOfficerMember 2025-08-28 2025-08-28 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001711786 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001711786 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001711786 rkto:ATMAgreementMember 2024-11-08 2026-11-12 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2024-11-08 2026-11-12 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2026-01-01 2026-09-30 0001711786 rkto:HCWainwrightCoLLCMember 2024-11-08 2024-11-08 0001711786 us-gaap:CommonStockMember 2025-01-13 0001711786 rkto:PatentApplicationAcquisitionAgreementMember 2025-01-13 2025-01-13 0001711786 us-gaap:CommonStockMember rkto:AprilTwoThousandTwentyFourInducementWarrantsMember 2025-01-07 2025-01-07 0001711786 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001711786 us-gaap:SeriesBPreferredStockMember 2026-09-30 0001711786 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2022-11-02 0001711786 us-gaap:SeriesAPreferredStockMember 2026-09-30 0001711786 us-gaap:PreferredStockMember 2025-12-31 0001711786 us-gaap:PreferredStockMember 2026-09-30 0001711786 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001711786 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001711786 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-12-31 0001711786 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-09-30 0001711786 us-gaap:TradeNamesMember 2026-09-30 0001711786 us-gaap:CustomerRelationshipsMember 2026-09-30 0001711786 2026-09-21 0001711786 2026-09-21 2026-09-21 0001711786 2026-10-31 0001711786 2026-10-01 2026-10-31 0001711786 2026-07-14 2026-07-14 0001711786 2026-07-14 0001711786 2025-09-23 0001711786 srt:MaximumMember rkto:ClassNCommonStockMember 2025-09-23 2025-09-23 0001711786 srt:MinimumMember rkto:ClassNCommonStockMember 2025-09-23 2025-09-23 0001711786 rkto:ClassNCommonStockMember 2025-09-23 0001711786 rkto:ClassCCommonShareMember 2025-09-23 0001711786 rkto:ZylTherapeuticsMember rkto:ClassNCommonStockMember 2025-09-23 2025-09-23 0001711786 rkto:ZylTherapeuticsMember 2025-09-23 0001711786 rkto:ZylTherapeuticsMember 2024-07-03 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2024-02-23 2024-02-23 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2024-02-23 0001711786 rkto:ZylTherapeuticsMember 2026-09-30 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2026-09-30 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2025-12-31 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2024-02-29 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2021-12-06 0001711786 rkto:ZylTherapeuticsMember us-gaap:CommonClassBMember 2020-05-04 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-07-01 2026-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-01-01 2026-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-12-31 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-06-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2026-06-30 0001711786 us-gaap:FairValueInputsLevel3Member 2025-12-31 0001711786 us-gaap:FairValueInputsLevel1Member 2025-12-31 0001711786 us-gaap:FairValueInputsLevel3Member 2026-09-30 0001711786 rkto:PatentApplicationsSoftwareAndOtherTechnologiesMember 2026-01-01 2026-09-30 0001711786 2026-06-18 2026-06-18 0001711786 rkto:PatentApplicationAcquisitionAgreementMember 2025-01-01 2025-09-30 0001711786 rkto:VAAgreementMember 2026-01-01 2026-09-30 0001711786 rkto:VAAgreementMember 2026-07-01 2026-09-30 0001711786 rkto:VCULicenseAgreementMember 2025-01-01 2025-09-30 0001711786 rkto:VCULicenseAgreementMember 2025-07-01 2025-09-30 0001711786 rkto:NationalAeronauticsAndSpaceAdministrationNASAMember 2026-01-01 2026-09-30 0001711786 rkto:NationalAeronauticsAndSpaceAdministrationNASAMember 2026-07-01 2026-09-30 0001711786 rkto:UniversityOfCincinnatiMember 2025-01-01 2025-09-30 0001711786 rkto:UniversityOfCincinnatiMember 2026-01-01 2026-09-30 0001711786 rkto:UniversityOfCincinnatiMember 2026-07-01 2026-09-30 0001711786 rkto:NorthCarolinaStateUniversityMember 2025-01-01 2025-09-30 0001711786 rkto:NorthCarolinaStateUniversityMember 2025-07-01 2025-09-30 0001711786 rkto:TheGeorgeWashingtonUniversityMember 2025-01-01 2025-09-30 0001711786 rkto:TheGeorgeWashingtonUniversityMember 2025-07-01 2025-09-30 0001711786 rkto:PatentApplicationsSoftwareAndOtherTechnologiesAcquiredMember 2025-01-01 2025-09-30 0001711786 rkto:PatentApplicationsSoftwareAndOtherTechnologiesAcquiredMember 2026-01-01 2026-09-30 0001711786 rkto:PatentApplicationsSoftwareAndOtherTechnologiesAcquiredMember 2026-07-01 2026-09-30 0001711786 rkto:USDepartmentOfVeteranAffairsMember 2026-01-01 2026-09-30 0001711786 rkto:USDepartmentOfVeteranAffairsMember 2026-07-01 2026-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember 2026-01-01 2026-09-30 0001711786 rkto:SOLSolanaMember 2025-12-31 0001711786 rkto:ETHEthereumMember 2025-12-31 0001711786 rkto:BTCBitcoinMember 2025-12-31 0001711786 rkto:TracerMember 2026-09-21 2026-09-30 0001711786 rkto:TracerDroneTechnologiesMember 2026-01-01 2026-09-30 0001711786 rkto:TracerDroneTechnologiesMember 2026-09-30 0001711786 rkto:TracerMember 2026-09-21 2026-09-21 0001711786 us-gaap:StockOptionMember 2025-01-01 2025-09-30 0001711786 us-gaap:StockOptionMember 2026-01-01 2026-09-30 0001711786 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001711786 us-gaap:WarrantMember 2026-01-01 2026-09-30 0001711786 2025-07-04 2025-07-04 0001711786 srt:MaximumMember 2026-09-30 0001711786 srt:MinimumMember 2026-09-30 0001711786 rkto:LimitedPartnershipMember srt:MaximumMember 2026-01-01 2026-09-30 0001711786 rkto:LimitedPartnershipMember srt:MinimumMember 2026-01-01 2026-09-30 0001711786 rkto:TracerDroneTechnologiesLLCMember 2026-09-21 0001711786 rkto:ATMAgreementMember 2026-04-01 2026-04-01 0001711786 rkto:ATMAgreementMember us-gaap:CommonStockMember 2026-09-30 0001711786 rkto:HCWainwrightCoLLCMember rkto:ATMAgreementMember 2026-07-01 2026-09-30 0001711786 rkto:ATMAgreementMember 2026-07-01 2026-09-30 0001711786 rkto:GoingConcernConsiderationsMember 2025-01-01 2025-09-30 0001711786 rkto:GoingConcernConsiderationsMember 2026-01-01 2026-09-30 0001711786 2024-12-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0001711786 us-gaap:RetainedEarningsMember 2025-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001711786 us-gaap:CommonStockMember 2025-09-30 0001711786 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001711786 2025-06-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001711786 us-gaap:RetainedEarningsMember 2025-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001711786 us-gaap:CommonStockMember 2025-06-30 0001711786 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001711786 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001711786 2025-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001711786 us-gaap:RetainedEarningsMember 2025-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001711786 us-gaap:CommonStockMember 2025-03-31 0001711786 2025-01-01 2025-03-31 0001711786 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001711786 us-gaap:RetainedEarningsMember 2024-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001711786 us-gaap:CommonStockMember 2024-12-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0001711786 us-gaap:RetainedEarningsMember 2026-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0001711786 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0001711786 2026-06-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0001711786 us-gaap:RetainedEarningsMember 2026-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001711786 us-gaap:CommonStockMember 2026-06-30 0001711786 2026-04-01 2026-06-30 0001711786 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001711786 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001711786 2026-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0001711786 us-gaap:RetainedEarningsMember 2026-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001711786 us-gaap:CommonStockMember 2026-03-31 0001711786 2026-01-01 2026-03-31 0001711786 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0001711786 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0001711786 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0001711786 us-gaap:RetainedEarningsMember 2025-12-31 0001711786 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001711786 us-gaap:CommonStockMember 2025-12-31 0001711786 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001711786 2026-11-12 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2025-07-01 2025-09-30 0001711786 us-gaap:FairValueInputsLevel1Member 2026-09-30 0001711786 us-gaap:FairValueInputsLevel2Member 2026-09-30 0001711786 us-gaap:FairValueInputsLevel2Member 2025-12-31 0001711786 rkto:USDepartmentOfVeteranAffairsMember rkto:VAAgreementMember 2025-07-01 2025-09-30 0001711786 rkto:USDepartmentOfVeteranAffairsMember rkto:VAAgreementMember 2025-01-01 2025-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember rkto:VCULicenseAgreementMember 2025-07-01 2025-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember rkto:VCULicenseAgreementMember 2025-01-01 2025-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-01-01 2025-09-30 0001711786 rkto:EmployeeStockOptionAwardsMember 2026-07-01 2026-09-30 0001711786 rkto:EmployeeStockOptionAwardsMember 2025-07-01 2025-09-30 0001711786 rkto:NonEmployeeRestrictedStockAwardsMember 2025-07-01 2025-09-30 0001711786 rkto:NonEmployeeRestrictedStockAwardsMember 2025-01-01 2025-09-30 0001711786 rkto:NonemployeeStockWarrantAwardsMember 2026-07-01 2026-09-30 0001711786 rkto:NonemployeeStockWarrantAwardsMember 2026-01-01 2026-09-30 0001711786 us-gaap:ResearchAndDevelopmentExpense 2026-07-01 2026-09-30 0001711786 us-gaap:ResearchAndDevelopmentExpense 2026-01-01 2026-09-30 0001711786 us-gaap:GeneralAndAdministrativeExpense 2026-07-01 2026-09-30 0001711786 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2025-07-01 2025-09-30 0001711786 rkto:TheGeorgeWashingtonUniversityMember 2026-07-01 2026-09-30 0001711786 rkto:TheGeorgeWashingtonUniversityMember 2026-01-01 2026-09-30 0001711786 rkto:NorthCarolinaStateUniversityMember 2026-07-01 2026-09-30 0001711786 rkto:UniversityOfCincinnatiMember 2025-07-01 2025-09-30 0001711786 rkto:PatentApplicationAcquisitionAgreementMember 2026-01-01 2026-09-30 0001711786 rkto:PatentApplicationsSoftwareAndOtherTechnologiesAcquiredMember 2025-07-01 2025-09-30 0001711786 rkto:NationalAeronauticsAndSpaceAdministrationNASAMember 2025-07-01 2025-09-30 0001711786 rkto:NationalAeronauticsAndSpaceAdministrationNASAMember 2025-01-01 2025-09-30 0001711786 rkto:EmployeeRestrictedStockAwardMember 2026-07-01 2026-09-30 0001711786 rkto:EmployeeRestrictedStockAwardMember 2026-01-01 2026-09-30 0001711786 us-gaap:ResearchAndDevelopmentExpense 2025-07-01 2025-09-30 0001711786 us-gaap:ResearchAndDevelopmentExpense 2025-01-01 2025-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember 2026-07-01 2026-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember 2025-07-01 2025-09-30 0001711786 rkto:USDepartmentOfVeteranAffairsMember 2025-07-01 2025-09-30 0001711786 rkto:NorthCarolinaStateUniversityMember 2026-01-01 2026-09-30 0001711786 rkto:VirginiaCommonwealthUniversityMember 2025-01-01 2025-09-30 0001711786 rkto:USDepartmentOfVeteranAffairsMember 2025-01-01 2025-09-30 0001711786 rkto:VCULicenseAgreementMember 2026-07-01 2026-09-30 0001711786 rkto:VCULicenseAgreementMember 2026-01-01 2026-09-30 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2025-01-01 2025-09-30 0001711786 rkto:AIInfrastructureAndTechnologiesSegmentMember 2025-12-31 iso4217:USD iso4217:USD xbrli:shares xbrli:shares xbrli:pure rkto:Segment

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the Quarterly Period Ended: September 30, 2026

 

or

 

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from:

 

Commission File Number: 001-38803

 

Rocket One Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   82-1553794
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

720 Monroe Street, Suite E514,

Hoboken, NJ

  07030
(Address of principal executive offices)   (Zip Code)

 

(866) 239-7459

(Registrant’s telephone number, including area code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading symbol(s)   Name of each exchange on which registered
Common Stock, $0.0001 par value   RKTO   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

The number of shares of the issuer’s common stock, $0.0001 par value per share, outstanding at November 12, 2026 was 24,897,581.

 

 

 

 

 

  

Table of Contents

 

  Page
PART I - FINANCIAL INFORMATION 1
ITEM 1. Financial Statements 1
  Condensed Consolidated Balance Sheets as of September 30, 2026 (Unaudited) and December 31, 2025 1
  Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) 2
  Condensed Consolidated Statements of Changes in Stockholders’ Equity for the Three and Nine Months Ended September 30, 2026 and 2025 (Unaudited) 3
  Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2026 and 2025 (Unaudited) 4
  Notes to Unaudited Condensed Consolidated Financial Statements 5
ITEM 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 30
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk 37
ITEM 4. Controls and Procedures 37
     
PART II - OTHER INFORMATION 38
ITEM 1. Legal Proceedings 38
ITEM 1A. Risk Factors 38
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 38
ITEM 3. Defaults Upon Senior Securities 38
ITEM 5. Other Information 38
ITEM 6. Exhibits 39
SIGNATURES 40

 

-i-

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

 

This Quarterly Report on Form 10-Q contains certain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as “may,” “should,” “believes,” “will,” “expects,” “anticipates,” “estimates,” “predicts,” “potential,” “continues,” “intends,” “plans” and “would” or the negative of these terms or other comparable terminology. For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Our forward-looking statements are based on a series of expectations, assumptions, estimates and projections about our company, are not guarantees of future results or performance and involve substantial risks and uncertainty. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this Quarterly Report on Form 10-Q. Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding:

 

● our business strategies, including our strategic repositioning;

 

  ● the development potential of the licensed technologies and the suitability of those technologies for orbital, defense, and other applications;
     
  ● anticipated future operations and market opportunities;
     
  ● risks related to market acceptance of our products and technologies;
     
  ● intellectual property risks;
     
  ● our industry environment;
     
  ● our anticipated financial and operating results, including anticipated sources of revenues;
     
  ● assumptions regarding the size of the available market, benefits of our products and technologies, pricing and timing of product launches;
     
  ● management’s expectation with respect to future acquisitions;
     
  ● statements regarding our goals, intentions, plans and expectations, including the introduction of new products, technologies and markets;
     
  ● general business and economic conditions, such as inflationary pressures, geopolitical conditions and tariffs and other trade barriers;
     
  ● government regulations;
     
  ● our cash needs and financing plans;

 

-ii-

 

  

  ● our ability to execute our growth strategy and scale our operations efficiently, including managing costs, timelines, and operational complexity;  
     
  ● our ability to design, develop and successfully commercialize new and innovative technologies, products, and services;  
     
  ● the amount, nature and timing of our capital expenditures and the impact of such capital expenditures on our growth and performance, including our ability to fund such expenditures, manage costs and achieve expected returns on investment;  
     
  ● our ability to obtain and maintain required regulatory approvals, licenses and authorizations in the United States and internationally, and the timing, scope, and conditions of such approvals;  
     
  ● the competitive landscape in the industries in which we operate and our ability to compete effectively;
     
  ● the implementation, interpretation, and impact of current or future regulations including laws and regulations relating to space operations, communications, AI, data privacy, and other areas;  
     
  ● the timing of regulatory submissions;

 

  ● our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;

 

  ● compromise, damage or interruptions from cybersecurity incidents or other data or system security risks;

 

  ● risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;

 

  ● the ultimate impact of any public health crisis on our business, our clinical trials, our research programs, healthcare systems or the global economy as a whole; and

 

  ● risks associated with our reliance on third-party organizations.

 

All of our forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”) could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q.

 

This Quarterly Report on Form 10-Q may include market data and certain industry data and forecasts, which we may obtain from internal company surveys, market research, consultant surveys, publicly available information, reports of governmental agencies and industry publications, articles and surveys. Industry surveys, publications, consultant surveys and forecasts generally state that the information contained therein has been obtained from sources believed to be reliable, but the accuracy and completeness of such information is not guaranteed. While we believe that such studies and publications are reliable, we have not independently verified market and industry data from third-party sources.

 

-iii-

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS.

 

ROCKET ONE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

 

    September 30,     December 31,  
    2026     2025  
    (Unaudited)        
ASSETS            
             
CURRENT ASSETS:            
Cash and cash equivalents   $ 6,016,055     $ 6,247,467  
Accounts receivable     4,523       -  
Prepaid expenses and other current assets     836,197       366,548  
Crypto assets, at fair value     -       191,367  
Deferred offering costs     -       57,171  
Total Current Assets     6,856,775       6,862,553  
                 
NON-CURRENT ASSETS:                
Prepaid expenses and other assets, net of current portion     967,135       699,420  
Operating lease right-of-use asset, net     -       4,652  
Intangible assets, net     208,846       -  
Goodwill     590,794       -  
Investment in joint ventures at fair value     36,819       36,819  
Total Non-Current Assets     1,803,594       740,891  
                 
Total Assets   $ 8,660,369     $ 7,603,444  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
CURRENT LIABILITIES:                
Accounts payable   $ 695,785     $ 823,674  
Accrued expenses     540,779       623,323  
Operating lease liability, current portion     -       5,678  
Total Current Liabilities     1,236,564       1,452,675  
                 
Total Liabilities     1,236,564       1,452,675  
                 
Commitments and Contingencies (Note 11)                
                 
STOCKHOLDERS’ EQUITY:                
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025     -       -  
Series A Convertible Preferred Stock, $0.0001 par value;  5,000,000 shares designated; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025     -       -  
Series B Preferred Stock, $0.0001 par value;  2,000,000 shares designated; 0 shares issued and outstanding as of September 30, 2026 and December 31, 2025     -       -  
Common stock, $0.0001 par value; 50,000,000 shares authorized; 24,897,581 and 15,514,312 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively     2,490       1,551  
Additional paid-in capital     89,497,363       79,017,730  
Accumulated deficit     (82,085,652 )     (72,879,343 )
Accumulated other comprehensive income     9,604       10,831  
Total Stockholders’ Equity     7,423,805       6,150,769  
                 
Total Liabilities and Stockholders’ Equity   $ 8,660,369     $ 7,603,444  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

 

ROCKET ONE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(Unaudited)

 

    For the Three Months Ended     For the Nine Months Ended  
    September 30,     September 30,  
    2026     2025     2026     2025  
                         
NET REVENUES   $ 35     $ -     $ 35     $ -  
                                 
OPERATING COSTS AND EXPENSES:                                
Research and development expense     1,123,484       1,633,476       4,597,860       4,631,791  
General and administrative expenses     1,405,894       2,447,188       4,414,767       5,124,539  
                                 
Total operating expenses     2,529,378       4,080,664       9,012,627       9,756,330  
                                 
LOSS FROM OPERATIONS     (2,529,343 )     (4,080,664 )     (9,012,592 )     (9,756,330 )
                                 
OTHER INCOME (EXPENSES), NET:                                
Realized and unrealized loss on crypto assets     -       (25,305 )     (44,165 )     (25,305 )
Impairment loss on equity securities without readily determinable fair value     (150,000 )     -       (150,000 )     -  
Interest income     150       168       448       522  
                                 
Total other income (expenses), net     (149,850 )     (25,137 )     (193,717 )     (24,783 )
                                 
NET LOSS   $ (2,679,193 )   $ (4,105,801 )   $ (9,206,309 )   $ (9,781,113 )
                                 
NET LOSS PER COMMON SHARE:                                
Basic and diluted   $ (0.11 )   $ (0.30 )   $ (0.45 )   $ (0.74 )
                                 
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING:                                
Basic and diluted     24,711,391       13,787,159       20,383,239       13,197,775  
                                 
COMPREHENSIVE LOSS:                                
Net loss   $ (2,679,193 )   $ (4,105,801 )   $ (9,206,309 )   $ (9,781,113 )
                                 
Other comprehensive income (loss):                                
Foreign currency translation adjustment     (1,737 )     (1,016 )     (1,227 )     1,965  
                                 
Total comprehensive loss   $ (2,680,930 )   $ (4,106,817 )   $ (9,207,536 )   $ (9,779,148 )

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

ROCKET ONE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2026 AND 2025

(Unaudited)

 

                Additional           Accumulated Other     Total  
    Common Stock     Paid-in     Accumulated     Comprehensive     Stockholders’  
    Shares     Amount     Capital     Deficit     Income (Loss)     Equity  
                                     
Balance, December 31, 2025     15,514,312     $ 1,551     $ 79,017,730     $ (72,879,343 )   $ 10,831     $ 6,150,769  
Common stock issued for cash, net     756,187       76       701,408       -       -       701,484  
Cumulative translation adjustment     -       -       -       -       1,578       1,578  
Net loss     -       -       -       (2,692,465 )     -       (2,692,465 )
                                                 
Balance, March 31, 2026     16,270,499       1,627       79,719,138       (75,571,808 )     12,409       4,161,366  
Common stock issued for cash, net     3,436,991       343       5,145,236       -       -       5,145,579  
Common stock and warrants issued for cash, net     2,857,144       286       1,611,594       -       -       1,611,880  
Issuance of common stock issued for professional fees     620,000       62       492,488       -       -       492,550  
Stock-based stock option expense     -       -       625,485       -       -       625,485  
Cumulative translation adjustment     -       -       -       -       (1,068 )     (1,068 )
Net loss     -       -       -       (3,834,651 )     -       (3,834,651 )
                                                 
Balance, June 30, 2026     23,184,634       2,318       87,593,941       (79,406,459 )     11,341       8,201,141  
Common stock issued for cash, net     1,712,947       172       1,903,422       -       -       1,903,594  
Cumulative translation adjustment     -       -       -       -       (1,737 )     (1,737 )
Net loss     -       -       -       (2,679,193 )     -       (2,679,193 )
                                                 
Balance, September 30, 2026     24,897,581     $ 2,490     $ 89,497,363     $ (82,085,652 )   $ 9,604     $ 7,423,805  

 

                Additional           Accumulated Other     Total  
    Common Stock     Paid-in     Accumulated     Comprehensive     Stockholders’  
    Shares     Amount     Capital     Deficit     Income (Loss)     Equity  
                                     
Balance, December 31, 2024     8,042,747     $ 804     $ 67,279,033     $ (60,410,041 )   $ 9,063     $ 6,878,859  
Common stock issued for exercise of warrants     3,750,000       375       5,624,625       -       -       5,625,000  
Stock-based compensation     -       -       219,929       -       -       219,929  
Common stock issued for cash, net     927,968       93       1,441,871       -       -       1,441,964  
Common stock issued for patent     450,000       45       850,455       -       -       850,500  
Cumulative translation adjustment     -       -       -       -       (497 )     (497 )
Net loss     -       -       -       (3,475,836 )     -       (3,475,836 )
                                                 
Balance, March 31, 2025     13,170,715       1,317       75,415,913       (63,885,877 )     8,566       11,539,919  
Issuance of warrants for professional fees     -       -       333,150       -       -       333,150  
Common stock issued for cash, net     63,312       6       66,095       -       -       66,101  
Cumulative translation adjustment     -       -       -       -       3,478       3,478  
Net loss     -       -       -       (2,199,476 )     -       (2,199,476 )
                                                 
Balance, June 30, 2025     13,234,027       1,323       75,815,158       (66,085,353 )     12,044       9,743,172  
Common stock issued for cash, net     1,404,339       141       2,003,350       -       -       2,003,491  
Common stock issued for compensation, net of tax withholding     489,256       49       591,951       -       -       592,000  
Cumulative translation adjustment     -       -       -       -       (1,016 )     (1,016 )
Net loss     -       -       -       (4,105,801 )     -       (4,105,801 )
                                                 
Balance, September 30, 2025     15,127,622     $ 1,513     $ 78,410,459     $ (70,191,154 )   $ 11,028     $ 8,231,846  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

 

ROCKET ONE, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

 

    For the Nine Months Ended  
    September 30,  
    2026     2025  
CASH FLOWS FROM OPERATING ACTIVITIES:            
Net loss   $ (9,206,309 )   $ (9,781,113 )
Adjustments to reconcile net loss to net cash used in operating activities:                
Research and development-acquired patent, expensed     -       850,500  
Stock-based compensation     625,485       1,187,929  
Stock-based professional fees     174,731       222,100  
Impairment loss on equity securities without readily determinable fair value     150,000       -  
Lease costs     (1,026 )     2,135  
Realized and unrealized loss on crypto assets     44,165       25,305  
Changes in operating assets and liabilities:                
Prepaid expenses and other current assets     (318,823 )     (356,643 )
Accounts payable and accrued expenses     (272,636 )     196,254  
                 
NET CASH USED IN OPERATING ACTIVITIES     (8,804,413 )     (7,653,533 )
                 
CASH FLOWS FROM INVESTING ACTIVITIES:                
Proceeds from sale of crypto assets     147,202       -  
Purchase of crypto assets     -       (300,000 )
Cash used for acquisition     (742,682 )     -  
Investment in equity securities without readily determinable fair value     (250,000 )     -  
                 
NET CASH USED IN INVESTING ACTIVITIES     (845,480 )     (300,000 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES:                
Proceeds from issuance of common stock, net of offering costs     7,750,657       3,511,556  
Proceeds from issuance of common stock and warrants, net of offering costs     1,669,051       -  
Proceeds from exercise of warrants     -       5,625,000  
Taxes paid related to net share settlement of equity award     -       (376,000 )
                 
NET CASH PROVIDED BY FINANCING ACTIVITIES     9,419,708       8,760,556  
                 
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS     (230,185 )     807,023  
                 
Effect of exchange rate changes on cash and cash equivalents     (1,227 )     1,965  
                 
CASH AND CASH EQUIVALENTS  - beginning of period     6,247,467       7,038,923  
                 
CASH AND CASH EQUIVALENTS  - end of period   $ 6,016,055     $ 7,847,911  
                 
NON-CASH INVESTING AND FINANCING ACTIVITIES:                
Common stock issued for future services   $ 492,550     $ -  
Reclassification of deferred offering costs to additional paid-in capital   $ 57,171     $ -  
Increase in prepaid expenses and other current assets and additional paid-in capital from the issuance of warrants   $ -     $ 333,150  
Reclassification of investment in equity securities without readily determinable fair value to prepaid expenses and other current assets   $ 100,000     $ -  
ACQUISITION:            
Assets acquired:            
Accounts receivable   $ 4,523     $ -  
Other current assets     722       -  
Intangible assets     208,846       -  
Goodwill     590,794       -  
Total assets acquired     804,885       -  
Less liabilities assumed:                
Accounts payable     12,727       -  
Accrued expenses     49,476       -  
Total liabilities assumed     62,203       -  
Net assets acquired, excluding cash   $ 742,682     $ -  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS OPERATIONS

 

Rocket One Inc. (together with its wholly-owned subsidiaries, merveille.ai, Hoth Therapeutics, Inc. (formerly Hoth Therapeutics, LLC), Rocket One.0 Inc., Hoth Therapeutics Australia Pty Ltd., and Tracer Drone Technologies, LLC, the “Company”) was incorporated under the laws of the State of Nevada on May 16, 2017. On May 26, 2026, the Company changed its name from Hoth Therapeutics, Inc. to Rocket One Inc. The Company is an Artificial Intelligence (“AI”) semiconductor infrastructure company building nanomagnetic and spintronic computing for ultra-low-power AI, resilient edge, defense, and space. The Company is focused on developing (i) a nanomagnetic matrix multiplier; (ii) Skyrmion Spintronic memory; and (iii) Swarm Stage AI. The Company also has preclinical and clinical assets that will be developed under its wholly owned subsidiary Hoth Therapeutics, Inc. for (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); (iii) a treatment for obesity, and obesity-related diseases and conditions (HT-VA); and (iv) a treatment for Alzheimer’s Disease (HT-ALZ). 

 

On September 18, 2026, the Company entered into a definitive Membership Interest Purchase Agreement to acquire all of the issued and outstanding membership interests of Tracer Drone Technologies, LLC (“Tracer”), a New Jersey-based provider of drone hardware, software, training, maintenance and managed services. On September 21, 2026, the Company closed on the Membership Interest Purchase Agreement and acquired 100% of Tracer’s membership interests. The acquisition of Tracer adds an established, revenue-generating commercial platform and combines operating drone capabilities with the Company’s broader AI, space, and defense technology strategy.

  

Going Concern Considerations

 

In accordance with Accounting Standards Codification (“ASC”) 205-40, Presentation of Financial Statements – Going Concern, management evaluates whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. If such substantial doubt exists, management then evaluates whether its plans, when implemented, are probable of alleviating that doubt. Disclosure is required when substantial doubt is raised, whether or not management’s plans alleviate it.

 

The accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses and negative cash flows from operations since its inception and has historically funded its operations through the sale of equity securities. As of September 30, 2026, the Company had an accumulated deficit of $82,085,652, cash and cash equivalents of $6,016,055 and working capital of $5,620,211. Net cash used in operating activities was $8,804,413 and $7,653,533 for the nine months ended September 30, 2026 and 2025, respectively. The Company incurred net losses of $9,206,309 and $9,781,113 for the nine months ended September 30, 2026 and 2025, respectively.

 

The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its research and development (“R&D”) activities and meet its obligations as they come due. The Company will require significant additional capital to make the investments it needs to execute its longer-term business plan. The Company’s ability to successfully raise sufficient funds through the sale of debt or equity securities when needed is subject to many risks and uncertainties. Even if it were successful, future equity issuances may result in dilution to its existing shareholders and future debt securities may contain covenants that limit the Company’s operations or ability to enter into certain transactions.

 

On August 6, 2026, the Company was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Under the Notification Letter, the Company has 180 calendar days, or until February 2, 2027, to regain compliance. If the Company does not regain compliance by February 2, 2027, an additional 180 days may be granted to regain compliance, if the Company meets The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notifies Nasdaq in writing of its intention to cure the deficiency during the second compliance period. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance, including a reverse stock split.

 

Management does not believe the Company’s current cash is sufficient to fund operations for at least one year from the date these unaudited condensed consolidated financial statements are issued. The Company will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to continue developing and seeking regulatory approvals for current and future products and technologies. If such funding is not available, or not available on terms acceptable to the Company, the Company’s current development plan and plans for expansion of its general and administrative infrastructure may be curtailed. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued. These unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern.

  

5

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

On November 8, 2024, the Company entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) under which the Company could offer and sell shares of its common stock through Wainwright as the sales agent (see Note 10). During the nine months ended September 30, 2026, the Company sold an aggregate of 5,906,125 shares of its common stock for net proceeds of $7,750,657, or $1.31 per share. As of September 30, 2026, the aggregate market value of the shares of common stock remaining eligible for sale is currently $5,257,000.

  

On April 1, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell to such investors 2,857,144 shares of common stock of the Company at a purchase price of $0.70 per share of common stock. Gross proceeds from the offering were approximately $2,000,000, and the Company received net proceeds of $1,611,880, after deducting placement agent’s fees and other offering expenses paid by the Company of $388,121 (see Note 10).

  

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation and Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual consolidated financial statements prepared in accordance with GAAP have been condensed or omitted. These unaudited condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on March 27, 2026.

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company’s wholly-owned subsidiaries, merveille.ai, which was incorporated under the laws of Nevada on October 4, 2023, Rocket One.0 Inc., which was incorporated under the laws of Nevada on April 22, 2026, Hoth Therapeutics, Inc. (formerly Hoth Therapeutics, LLC, a limited liability company which was formed under the laws of Nevada on June 17, 2026, and subsequently converted to Hoth Therapeutics, Inc., a corporation under the laws of Nevada on September 18, 2026), Hoth Therapeutics Australia Pty Ltd, which was incorporated under the laws of the State of Victoria in Australia on June 5, 2019, and Tracer since September 21, 2026, the date the Company acquired 100% of Tracer’s membership interests. All significant intercompany balances and transactions have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to stock-based compensation, the valuation of intangible assets acquired, the valuation of common stock issued for services, and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations may be affected.

 

6

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents consist of bank accounts and highly liquid money funds and totaled $6,016,055 and $6,247,467 as of September 30, 2026 and December 31, 2025, respectively. Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash deposits at the three financial institutions the Company utilizes for its banking requirements. The Company’s foreign bank account is not subject to Federal Deposit Insurance Corporation insurance. Cash held in foreign bank accounts totaled approximately $87,000 and $96,000 as of September 30, 2026 and December 31, 2025, respectively.

 

Accounts Receivable

 

The Company follows Accounting Standards Codification (“ASC”) 326, “Financial Instruments - Credit Losses”, and recognizes an allowance for losses on accounts and notes receivable in an amount equal to the estimated probable losses net of recoveries under the current expected credit loss method. The allowance is based on an analysis of historical credit loss experience, current receivables aging, and expected future write-offs, as well as an assessment of specific identifiable customer accounts considered at risk or uncollectible. The credit loss expense associated with the allowance for doubtful accounts related to accounts receivable is recognized in general and administrative expenses. As of September 30, 2026 and December 31, 2025, accounts receivable amounted to $4,523 and $0, respectively. For the nine months ended September 30, 2026 and 2025, the Company did not recognize any credit losses.

 

Concentrations of Credit Risk and Off-Balance Sheet Risk

 

The Company has significant cash balances at financial institutions which, throughout the year, regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.

  

Fair Value of Financial Instruments

 

Financial Accounting Standards Board (“FASB”) ASC 820, Fair Value Measurements (“ASC 820”), provides guidance on the development and disclosure of fair value measurements. Under this accounting guidance, fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability.

 

The fair value of the Company’s assets and liabilities, which would qualify as financial instruments under ASC 820, approximates the carrying amounts represented in the Company’s condensed consolidated balance sheets, primarily due to their short-term nature.

 

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

 

  Level 1: Quoted prices in active markets for identical assets or liabilities.
     
  Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.
     
  Level 3: Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

 

In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. During the nine months ended September 30, 2026 and 2025, there were no changes in valuation techniques or transfers between Level 1, Level 2, and Level 3.

 

7

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Business Acquisition

 

The Company accounted for its business acquisition using the acquisition method of accounting where the assets acquired and liabilities assumed are recognized based on their respective estimated fair values. Identifiable intangible assets acquired are recorded at their estimated fair values, and the excess of the purchase price over the fair value of the net assets acquired, including identifiable intangible assets, is recorded as goodwill. Determining the fair value of certain acquired assets and liabilities was subjective in nature and often involves the use of significant estimates and assumptions, including, but not limited to, the selection of appropriate valuation methodology, projected revenue, expenses, and cash flows, weighted average cost of capital, discount rates, and estimates of terminal values. The business acquisition was included in the Company’s consolidated financial statements as of the date of the acquisition (see Note 3).

 

Leases

 

The Company determines if an arrangement is a lease at inception and classifies its leases at commencement. Operating leases are presented as right-of-use (“ROU”) assets and the corresponding lease liabilities are included in operating lease liability, current and lease liability, on the Company’s condensed consolidated balance sheets. ROU assets represent the Company’s right to use an underlying asset, and lease liabilities represent the Company’s obligation to make lease payments in exchange for the ability to use the asset for the duration of the lease term.

 

The Company may have lease agreements which contain both lease and non-lease components, which it has elected to account for as a single lease component. As such, minimum lease payments include fixed payments for non-lease components within a lease agreement but exclude variable lease payments not dependent on an index or rate, such as common area maintenance, operating expenses, utilities, or other costs that are subject to fluctuation from period to period. Certain of the leases may contain an option to extend the term of the lease. The option to extend a lease is included in the lease term only when it is reasonably certain that the Company will elect that option. Additionally, the Company does not record ROU assets or lease liabilities for short-term leases that have a term of twelve months or less at lease commencement.

  

ROU assets and lease liabilities are recognized at the commencement date and determined using the present value of the future minimum lease payments over the lease term. The Company uses an incremental borrowing rate based on an estimated rate of interest for collateralized borrowing since the Company’s leases do not include an implicit interest rate. The estimated incremental borrowing rate considers market data, actual lease economic environment, and the lease term at commencement date.

  

Investment in Joint Ventures

 

Ownership interests in entities for which the Company has significant influence that are not consolidated are accounted for as equity method investments. SEC Staff Announcement: Accounting for Limited Partnership Investments (codified in ASC 323-30-S99-1) guidance requires the use of the equity method unless the investor’s interest “is so minor that the limited partner may have virtually no influence over partnership operating and financial policies.” The SEC staff’s position is that investments in limited partnerships of greater than 3% to 5% are considered more than minor and, therefore, should be accounted for using the equity method or fair value option. Investments accounted for using the equity method may be reported on a lag up to three months if financial statements of the investee are not available in sufficient time for the investor to apply the equity method as of the current reporting date. The determination of whether an investee’s results are recorded on a lag is made on an investment-by-investment basis. This investment in joint ventures is further described in Note 6 of these unaudited condensed consolidated financial statements.

 

Equity Securities Without Readily Determinable Fair Values

 

The Company holds an equity investment in a privately held entity over which it does not have significant influence or control. Because the investment does not have a readily determinable fair value and does not qualify for the net asset value practical expedient, the Company has elected to measure it under the measurement alternative in ASC 321, Investments – Equity Securities. Under the measurement alternative, the investment is carried at cost, less any impairment, and adjusted up or down for observable price changes in orderly transactions for an identical or similar investment of the same issuer. Any such adjustments are recognized in other income (expense), net, in the condensed consolidated statements of operations.

 

At each reporting period, the Company performs a qualitative assessment to evaluate whether the investment is impaired. Impairment indicators considered include a significant deterioration in the investee’s earnings performance, credit rating, or business prospects; a significant adverse change in the regulatory, economic, or technological environment of the investee; a significant adverse change in the general market condition of the investee’s industry or geographic area; bona fide offers to purchase, or offerings by the investee to sell, the same or similar securities for an amount less than the carrying amount; and factors that raise significant concerns about the investee’s ability to continue as a going concern. If the qualitative assessment indicates the investment is impaired, the Company estimates its fair value and recognizes an impairment loss in net income equal to the amount by which the carrying value exceeds fair value.

 

8

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Digital Assets, at Fair Value

 

The Company’s digital assets primarily included Bitcoin (“BTC”), Ethereum (“ETH”) and Solana (“SOL”), which are actively traded on public exchanges. The Company distinguishes between digital assets which fall within the scope of ASC 350-60 and those which do not. The Company refers to digital assets which fall within the scope of ASC 350-60 (e.g., BTC) as “crypto assets.” Digital assets which do not fall within the scope of ASC 350-60, Accounting for and Disclosure of Crypto Assets, are referred to as “digital intangible assets.” As of September 30, 2026 and December 31, 2025, the Company did not own any digital intangible assets that did not fall within the scope of ASC 350-60.

 

Crypto assets are recorded at fair value in accordance with ASC 820, Fair Value Measurement. Changes in fair value are recognized in the Company’s unaudited condensed consolidated statements of operations and comprehensive loss within “other income (expenses), net” for the period in which they occur.

 

Digital assets are classified on the condensed consolidated balance sheets based on management’s intent and the expected period of use or sale:

 

● Current assets: Digital assets held for trading or intended to be sold within 12 months are classified as current assets.

 

● Non-current assets: Digital assets held for investment or long-term strategic purposes are classified as non-current assets.

 

The fair value of each cryptocurrency holding is based on the closing market price on the reporting date.

 

As of December 31, 2025, the Company held $191,367 of crypto assets comprised of BTC, ETH and SOL, which are in the scope of ASC 350-60 at fair value. In determining the fair value of the crypto assets in accordance with ASC 820, the Company utilizes Coinbase as the principal market. The Company uses a first-in, first-out methodology to assign costs to crypto assets. Sales and purchases of crypto assets are reflected as cash flows from investing activities in the unaudited condensed consolidated statements of cash flows. As of September 30, 2026, the Company did not hold any crypto assets.

 

Intangible Assets

 

Intangible assets, consisting of customer relationships and trade name, are carried at cost less accumulated amortization, computed using the straight-line method over the estimated useful life ranging from 7 to 15 years, less any impairment charges.

 

Goodwill

 

The Company’s business acquisition resulted in the recording of goodwill. Goodwill represented the excess of the purchase price paid over the fair value of the net assets acquired in the business acquisition. Goodwill is subject to impairment tests at least annually. The Company reviews the carrying amounts of goodwill by reporting unit at least annually, or when indicators of impairment are present, to determine if goodwill may be impaired. The Company includes assumptions about the expected future operating performance as part of a discounted cash flow analysis to estimate fair value. If the carrying value of these assets is not recoverable, based on the discounted cash flow analysis, management compares the fair value of the assets to the carrying value. Goodwill is considered impaired if the recorded value exceeds the fair value. The Company may first assess qualitative factors to determine whether it is more likely than not that the fair value of goodwill is less than its carrying value. The Company would not be required to quantitatively determine the fair value of goodwill unless it determines, based on the qualitative assessment, that it is more likely than not that its fair value is less than the carrying value. Future cash flows of the individual indefinite-lived intangible assets are used to measure their fair value after consideration of certain assumptions, such as forecasted growth rates and cost of capital, which are derived from internal projection and operating plans.

 

Revenue Recognition

 

The Company follows ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). This standard establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers. ASC 606 requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and requires certain additional disclosures.

 

9

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

In accordance with ASC 606 - Revenue from Contracts with Customers, the Company recognizes revenue in accordance with that core principle by applying the following steps:

 

Step 1: Identify the contract(s) with a customer.

Step 2: Identify the performance obligations in the contract.

Step 3: Determine the transaction price.

Step 4: Allocate the transaction price to the performance obligations in the contract.

Step 5: Recognize revenue when (or as) the entity satisfies a performance obligation.

  

The Company generates revenue from the following sources:

 

● Product sales, consisting of the sale of drones and drone accessories, are recognized at a point in time when the product is shipped to the customer and title is transferred and are recorded net of any discounts or allowances.

 

● Tracer generates revenue from the sale of training packages to its customers. Training packages consist of a series of drone training sessions.  Revenues generated from such sales are recognized at a point in time, which is upon the completion and the utilization of training sessions, which is when the Company completes its performance obligation. Any fees paid in advance by the customer are reflected as contract liabilities until such time as the performance obligation is completed.

 

● Tracer sells subscriptions to its customers for the use of certain software and subscription services. Revenues related to subscription agreements are recognized over the subscription period as services are performed.

 

Shipping and Handling Costs

 

Shipping and handling costs incurred for products shipped to customers are included in general and administrative expenses. Shipping and handling costs charged to customers are included in sales.

 

Research and Development Costs

 

Research and development costs, including acquired in-process research and development expenses for which there is no alternative future use, are expensed as incurred. Advance payments for goods and services that will be used in future research and development activities are accrued and then expensed when the activity has been performed or when the goods have been received rather than when the payment is made.

  

Stock-Based Compensation

 

The Company accounts for stock-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. Options are generally issued fully vested. The Company accounts for forfeited awards as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

10

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

 

The Company grants restricted stock awards under its equity incentive plan. Restricted stock awards are granted to employees and non-employees. The restricted stock awards are measured based on the grant-date fair value. In general, the restricted stock awards vest over a service period of zero to three years. Stock-based compensation expense is generally recognized based on the straight-line basis over the requisite service period and forfeitures are accounted for as they occur.

 

The Company has issued warrants to non-employees. The warrants are measured based on the grant-date fair value. In general, the warrants vest over a term of zero to ten years. Stock-based compensation expense is generally recognized based on the straight-line basis over the vesting term.

 

Income Taxes

 

Income taxes are recorded in accordance with ASC 740, Income Taxes (“ASC 740”), which provides for deferred taxes using an asset and liability approach. The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the unaudited condensed consolidated financial statements or tax returns. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided, if based upon the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

 

The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances.

 

On July 4, 2025, the One Big Beautiful Bill Act (“OBBBA”) was enacted into law. With the passing of this tax legislation, the most notable corporate tax issue that impacts the Company is the change to Internal Revenue Code (“IRC”) §174. Since 2022, the Company has been required to capitalize U.S. and foreign research and development expenditures in accordance with IRC §174 and amortize those costs over 5 years for U.S. costs and 15 years for foreign costs. The new legislation no longer requires U.S. research and development costs to be capitalized; however, foreign costs will continue to be capitalized and amortized over 15 years. U.S. costs that were capitalized in tax years 2022 through 2024 can be expensed. Pursuant to the OBBBA’s transition rules, in 2025, the Company elected to expense all unamortized domestic research and experimental (“R&E”) expenditures previously capitalized between 2022 and 2024. The Company continues to evaluate various elections available to the Company under OBBBA related to IRC §174 capitalized R&E expenditures. The effect of expensing all unamortized domestic R&E expenditures was to decrease the Company’s deferred tax assets and decrease the related valuation allowance.

  

Net Loss per Share

 

Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Since the Company had a net loss in the periods presented, basic and diluted net loss per share of common stock are the same. The following were excluded from the computation of diluted shares outstanding due to the losses for each period presented, as they would have had an anti-dilutive impact on the Company’s net loss:

 

    Nine Months Ended
September 30,
 
Potentially dilutive securities   2026     2025  
Warrants     4,683,821       1,740,752  
Options     2,310,362       1,260,362  
Total     6,994,183       3,001,114  

 

11

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Warrants

 

The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and in accordance with ASC 480, Distinguishing Liabilities from Equity (“ASC 480”), and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common shares, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

 

For issued warrants that meet all of the criteria for equity classification, the warrants are recorded as a component of additional paid-in capital at the time of issuance. For issued warrants that do not meet all the criteria for equity classification, the warrants are classified as liability and are required to be recorded at their initial fair value on the date of issuance, and each condensed consolidated balance sheet date thereafter.

 

Comprehensive Loss

 

Comprehensive loss is composed of net loss and other comprehensive income (loss). During the three and nine months ended September 30, 2026 and 2025, other comprehensive income (loss) was attributable to foreign currency translation adjustments.

 

Foreign Currency

 

The reporting currency of the Company is the U.S. dollar. For the Company’s subsidiary with non-U.S. dollar functional currencies, assets and liabilities are translated into U.S. dollars at period-end exchange rates. Revenue and expenses are translated at the average exchange rates during the period. Equity transactions are translated using historical exchange rates. The resulting translation adjustments are recorded in accumulated other comprehensive income – foreign currency translation as a component of stockholders’ equity. Foreign currency translation adjustments arising from differences in exchange rates from period to period are recorded within “Accumulated other comprehensive income – foreign currency translation” in the condensed consolidated balance sheets.

  

Segment Reporting

 

On January 1, 2024, the Company adopted FASB ASU 2023-07, Segment Reporting (ASC 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses among other disclosure requirements. Through March 31, 2026, the Company operated as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. During the nine months ended September 30, 2026, the Company began the process of transitioning primarily into an AI semiconductor infrastructure company building nanomagnetic and spintronic computing for ultra-low-power AI, resilient edge, defense, and space. Accordingly, beginning in the second quarter of 2026, the Company began operating in two reportable segments which consist of (1) a clinical-stage biopharmaceutical company, herein known as the “Biopharmaceutical” segment, and (2) an AI semiconductor infrastructure and other technologies company, herein known as the “AI Infrastructure and Technologies” segment. The Company has determined that these reportable segments are strategic business units that offer different products. These reportable segments shall be managed separately based on the fundamental differences in their operations.

 

In accordance with ASC 280, the Company’s chief operating decision maker has been identified as the Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire Company and decides how to allocate resources based on loss from operations, managing cash flows and evaluating research and development and general and administrative expenses. Existing guidance, which is based on a management approach to segment reporting, establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about products and services, major customers, and the countries in which the entity holds material assets and reports revenue. The Company has enhanced its segment disclosures in this report to include the presentation of two segments. The adoption of this ASU only affects the Company’s disclosures with no impact on its consolidated financial condition or results of operations. 

 

Recent Accounting Pronouncements

 

The Company adopted ASU 2023-09, Improvements to Income Tax Disclosures, during the year ended December 31, 2025 using a retrospective approach. The ASU requires greater disaggregation of information about a reporting entity’s effective tax rate reconciliation and information on income taxes paid. The ASU applies to all entities subject to income taxes and is intended to help investors better understand an entity’s exposure to potential changes in jurisdictional tax legislation and assess income tax information that affects cash flow forecasts and capital allocation decisions. The ASU is effective for annual periods beginning after December 15, 2024, with early adoption permitted. The adoption of ASU 2023-09 had no impact on the Company’s unaudited condensed consolidated financial statements.

 

12

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant line items, including, but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of this new guidance to have a material impact on its unaudited condensed consolidated financial statements.

 

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”) amending ASC 326, Credit Losses, which provides a practical expedient for all entities in developing reasonable and supportable forecasts as part of estimating expected credit losses to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company adopted ASU 2025-05 on January 1, 2026, and the adoption did not have a material impact on the Company’s unaudited condensed consolidated financial statements.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements, to provide clarity about the current requirements, rather than evaluate whether to expand or reduce interim disclosure requirements. The amendments in ASU 2025-11 result in a comprehensive list of interim disclosures that are required by GAAP. The amendments in ASU 2025-11 also include a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments in ASU 2025-11 are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 and early adoption is permitted. The amendments in ASU 2025-11 can be applied either prospectively or retrospectively to any or all prior periods presented in the unaudited condensed consolidated financial statements. The Company is currently evaluating the disclosure impact that ASU 2025-11 may have on its financial statement presentation and disclosures.

 

Currently, management does not believe that any other recently issued, but not yet effective accounting pronouncements, if currently adopted, would have a material impact on the Company’s unaudited condensed consolidated financial statements.

 

NOTE 3 – ACQUISITION

 

On September 21, 2026, the Company acquired all of the outstanding membership interests of Tracer, a New Jersey-based provider of drone hardware, software, training, maintenance and managed services for a cash purchase price of $800,000. $80,000 of the cash purchase price was deposited in an indemnification escrow with a third-party escrow agent for six months after signing, and the Company’s indemnification claims against the seller are generally capped at the escrow amount.

 

The assets acquired and liabilities assumed were recorded at their estimated fair values on the acquisition date and are subject to adjustment during the measurement period. These estimates are subject to refinement. Management developed estimates based on assumptions as a part of the purchase price allocation process to value the assets acquired and liabilities assumed as of the business acquisition date. As a result, during the purchase price measurement period, which may be up to one year from the business acquisition date, the Company may record adjustments to the assets acquired and liabilities assumed based on completion of updated valuations, with the corresponding offset to goodwill. Based upon the preliminary purchase price allocation, the following table summarizes the estimated fair value of the assets acquired and liabilities assumed at the date of the acquisition:

 

    September 21,
2026
 
Assets acquired:      
Cash   $ 57,318  
Accounts receivable     4,523  
Prepaid expenses and other assets     722  
Intangible assets     208,846  
Goodwill     590,794  
Total assets acquired at fair value     862,203  
Liabilities assumed:        
Accounts payable and accrued expenses     62,203  
Total liabilities assumed     62,203  
Net assets acquired   $ 800,000  
Purchase consideration paid:        
Cash paid   $ 800,000  
Total purchase consideration paid   $ 800,000  

 

13

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Factors that make up goodwill include an assembled workforce, which consists of a key Tracer employee retained under an employment agreement effective October 1, 2026, and a three-year non-competition and non-solicitation covenant from the seller.

 

The Company did not include supplemental pro forma revenue and earnings for the current and comparable prior periods since the inclusion of the supplemental pro forma revenue and earnings is impracticable.

 

In connection with the acquisition, during the three and nine months ended September 30, 2026, the Company incurred legal fees of $30,633, which is included in general and administrative expenses on the accompanying unaudited condensed consolidated statement of operations and comprehensive loss.

 

Effective as of September 21, 2026, the financial results of Tracer are included in the consolidated financial results of the Company. For the period from September 21, 2026 (acquisition date) to September 30, 2026, Tracer recorded revenues of $35 and a net loss of $2,576, which is included in the accompanying unaudited condensed consolidated statement of operations and comprehensive loss.

 

NOTE 4 – CRYPTO ASSETS, AT FAIR VALUE

 

As of September 30, 2026, the Company held no crypto assets.

 

The following table sets forth the units held, cost basis, and fair value of crypto assets held, as shown on the condensed consolidated balance sheet as of December 31, 2025:

 

    Classification     Units Held     Cost Basis     Fair Value at
December 31,
2025
 
Balance, December 31, 2025                        
BTC (Bitcoin)     Current       0.85673339     $ 100,000     $ 74,966  
ETH (Ethereum)     Current       21.96726563       100,000       65,176  
SOL (Solana)     Current       411.62365256       100,000       51,225  
Total                   $ 300,000     $ 191,367  

 

Cost basis is equal to the cost of the crypto assets plus transaction fees, if any, at the time of purchase or upon receipt. Fair value represents the quoted crypto asset prices within the crypto assets principal market at the time of measurement.

 

The following table represents a reconciliation of crypto assets held: 

 

    For the 
Nine Months
Ended
September 30,
2026
 
Fair Value, December 31, 2025   $ 191,367  
Crypto units sold, at fair value     (147,202 )
Realized loss     (44,165 )
Fair Value, September 30, 2026   $ -  

 

NOTE 5 – LICENSE, PATENTS, SOFTWARE AND OTHER TECHNOLOGIES AGREEMENTS

 

The following summarizes the Company’s research and development expenses for licenses, patents, software and other technologies acquired (including stock-based compensation) during the three and nine months ended September 30, 2026 and 2025:

 

    For the
Three Months Ended
September 30,
    For the
Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
The George Washington University   $ -     $ 1,250     $ -     $ 3,750  
North Carolina State University     -       937       -       2,812  
University of Cincinnati     2,500       -       2,500       3,333  
National Aeronautics and Space Administration (NASA)     21,667       -       21,667       -  
Virginia Commonwealth University     -       -       10,000       -  
U.S. Department of Veterans Affairs     6,250       -       43,750       -  
Patent applications, software and other technologies acquired     -       -       210,000       1,250,500  
    $ 30,417     $ 2,187     $ 287,917     $ 1,260,395  

 

14

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

The George Washington University

 

During the three and nine months ended September 30, 2026, the Company recorded expenses of $0 and $0, respectively, related to license fees pursuant to the patent license agreement with The George Washington University (“GW”) dated February 1, 2020 (“GW Patent License Agreement”) and the patent license agreement with GW dated August 7, 2020.

 

During the three and nine months ended September 30, 2025, the Company recorded expenses of $1,250 and $3,750, respectively, related to license fees pursuant to the GW Patent License Agreement and the patent license agreement with GW dated August 7, 2020.

 

North Carolina State University

 

During the three months ended September 30, 2026 and 2025, the Company recorded expenses of $0 and $937, respectively, for license fees associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021.

 

During the nine months ended September 30, 2026 and 2025, the Company recorded expenses of $0 and $2,812, respectively, for license fees associated with the license agreement by and between the Company and North Carolina State University dated February 25, 2021.

 

University of Cincinnati

 

During the three months ended September 30, 2026 and 2025, the Company recognized expenses of $2,500 and $0, respectively, for license fees associated with the Assignment and Assumption Agreement by and between the Company and the University of Cincinnati dated May 14, 2020.

 

During the nine months ended September 30, 2026 and 2025, the Company recognized expenses of $2,500 and $3,333, respectively, for license fees associated with the Assignment and Assumption Agreement by and between the Company and the University of Cincinnati dated May 14, 2020.

 

National Aeronautics and Space Administration (“NASA”)

 

During the three and nine months ended September 30, 2026, the Company recognized expenses of $21,667 and $21,667, respectively, for license fees associated with the Nonexclusive License Agreement by and between the Company and NASA dated July 28, 2026 (the “NASA License Agreement”).

 

During the three and nine months ended September 30, 2025, the Company did not recognize any expenses for license fees associated with the NASA License Agreement.

 

Virginia Commonwealth University

 

During the three and nine months ended September 30, 2026, the Company recognized expenses of $0 and $10,000, respectively, for license fees associated with the Exclusive License Agreement by and between the Company and Virginia Commonwealth University Intellectual Property Foundation dated May 15, 2026 (the “VCU License Agreement”).

 

During the three and nine months ended September 30, 2025, the Company did not recognize any expenses for license fees associated with the VCU License Agreement.

 

U.S. Department of Veterans Affairs

 

During the three and nine months ended September 30, 2026, the Company recognized expenses of $6,250 and $43,750, respectively, for license fees associated with the exclusive license agreement by and between the Company and the U.S. Department of Veterans Affairs dated December 9, 2024 (the “VA Agreement”).

 

During the three and nine months ended September 30, 2025, the Company did not recognize any expenses for license fees associated with the VA Agreement.

 

15

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Patent Applications, Software and Other Technologies

 

During the nine months ended September 30, 2026 and 2025, the Company recorded $0 and $1,250,500, respectively, for research and development expenses, associated with the Patent Application Acquisition Agreement by and between the Company and Med30 LLC dated January 13, 2025.

 

On June 18, 2026, the Company entered into an Asset Purchase Agreement with Skystage, Inc., whereby the Company purchased software and related technologies for the delivery of custom drone light shows using drone cluster technologies for $210,000 in cash. For asset acquisitions, in-process research and development (“IPRD”) is expensed immediately unless there is an alternative future use. The software and technologies acquired do not constitute a business, as defined under ASU 2017-01, Business Combinations (Topic 805) Clarifying the Definition of a Business (such as when there is no substantive process in the acquired entity). The acquired IPRD intangible assets will be used in research and development projects which have been determined to not have alternative future use at the acquisition date and were expensed immediately. Accordingly, during the nine months ended September 30, 2026, the Company recorded $210,000 in research and development expenses.

 

NOTE 6 – FAIR VALUE OF FINANCIAL ASSETS AND LIABILITIES

 

The following tables present the Company’s assets and liabilities that are measured at fair value on September 30, 2026 and December 31, 2025:

 

    Fair value measured at September 30, 2026  
    Total at
September 30,
2026
    Quoted
prices
in active
markets
(Level 1)
    Significant
other
observable
inputs
(Level 2)
    Significant
unobservable
inputs
(Level 3)
 
Assets:                        
Investment in joint ventures   $ 36,819     $        -     $        -     $ 36,819  

 

    Fair value measured at December 31, 2025  
    Total at
December 31,
2025
    Quoted
prices
in active
markets
(Level 1)
    Significant
other
observable
inputs
(Level 2)
    Significant
unobservable
inputs
(Level 3)
 
Assets:                        
Crypto assets   $ 191,367     $ 191,367     $ -     $ -  
Investment in joint ventures   $ 36,819     $ -     $       -     $ 36,819  

 

16

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Level 3 Measurement

 

The following table sets forth a summary of the changes in the fair value of the Company’s Level 3 financial assets that are measured at fair value on a recurring basis for the three and nine months ended September 30, 2026 and 2025:

 

Investment in joint ventures for the three months ended September 30, 2026 and 2025
 
    For the Three Months Ended
September 30,
 
    2026     2025  
Investment in joint ventures at fair value – beginning of period   $ 36,819     $ 36,819  
Change in fair value of investment in joint ventures     -       -  
Investment in joint ventures at fair value – end of period   $ 36,819     $ 36,819  

 

Investment in joint ventures for the nine months ended September 30, 2026 and 2025
 
    For the Nine Months Ended
September 30,
 
    2026     2025  
Investment in joint ventures at fair value – beginning of period   $ 36,819     $ 36,819  
Change in fair value of investment in joint ventures     -       -  
Investment in joint ventures at fair value – end of period   $ 36,819     $ 36,819  

 

Investment in equity securities without readily determinable fair value for the three and nine months ended
September 30, 2026 and 2025 (see Note 8)
 
    For the Three and Nine Months Ended
September 30,
 
    2026     2025  
Investment in equity securities without readily determinable fair value – beginning of period   $ -     $ -  
Investment in equity securities without readily determinable fair value     250,000       -  
Impairment loss on equity securities without readily determinable fair value     (150,000 )     -  
Reclassification of investment in equity securities without readily determinable fair value to prepaid expenses and other current assets     (100,000 )     -  
Investment in equity securities without readily determinable fair value – end of period   $ -     $ -  

 

17

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Investment in Joint Ventures

 

The Company has elected to measure the investment in joint ventures using the fair value option at each reporting date. Under the fair value option, bifurcation of an embedded derivative is not necessary, and all related gains and losses on the host contract and derivative due to change in the fair value will be reflected in other income (expenses), net in the unaudited condensed consolidated statements of operations and comprehensive loss.

 

The value at which the Company’s investment in joint ventures is carried on its books is adjusted to estimated fair value at the end of each quarter, taking into account general economic and stock market conditions and those characteristics specific to the underlying investments.

 

Investment in Zylö Therapeutics

 

In connection with the Company’s March 2020 underwritten public offering of shares of its common stock, on May 4, 2020, the Company purchased 120,000 shares of Zylö Therapeutics (“Zylö”) Class B common stock for $60,000. On December 8, 2021, the Company entered into a third amendment (the “Zylö Amendment”) to the Exclusive Sublicense Agreement with Zylö originally dated August 19, 2019 (as amended, the “Exclusive Sublicense Agreement”), pursuant to which the Company licensed its novel cannabinoid therapeutic, HT-005 for lupus patients, back to Zylö. Pursuant to the Zylö Amendment, on December 6, 2021, Zylö issued the Company 100,000 shares of its Class B common stock. In addition, pursuant to the Zylö Amendment, within 90 days following a sale by Zylö of all of its assets and rights related to HT-005 to a third-party (a “Sale”), Zylö shall pay the Company a low single digit percent of the net proceeds received by it attributable to HT-005 in the United States and Canada and their respective territories (collectively, the “Territory”) for the purposes of therapeutic uses related to lupus in humans (the “Field”). After the Sale, any and all rights of the Company pursuant to the Exclusive Sublicense Agreement, including all amendments thereto, shall terminate. Furthermore, pursuant to the Zylö Amendment, following the date of the first commercial sale of HT-005 in the Territory, in the Field, Zylö shall pay the Company (i) a low single digit percent of the Net Sales (as defined in the Exclusive Sublicense Agreement) of HT-005 in the event HT-005 is sold in the Territory and (ii) a low double digit percent of any royalty that Zylö receives through the sublicense to a third-party based on Net Sales of HT-005 in the Territory which payments shall continue in each country in the Territory until expiration of the last-to-expire Valid Claim (as defined in the Exclusive Sublicense Agreement). Zylö conducted a 409A valuation of their Class B common stock in February 2024, and as of September 30, 2026 and December 31, 2025, valued its 220,000 Zylö shares at $36,740, or at a price of $0.167 per share. This value was ratified by Zylö’s board of directors in February 2024.

 

On February 23, 2024, the Company acquired 22,000 shares of Class B common stock of Atticus Pharma, a subsidiary of Zylö Therapeutics, based upon a 1-for-10 ratio of current shares and was instructed, on July 3, 2024, that the 409A valuation of the shares was $79, or $0.0036 per share, pursuant to the February 2024 valuation ratified by Zylö’s board of directors.

 

On September 23, 2025, the Company received 110,000 shares of Class N common stock of Finch Pharma, a subsidiary of Zylö Therapeutics, based upon a 1-for-2 ratio of current shares and was instructed, on January 26, 2026, that a 409A valuation of $0.036 on each Class C common stock was done on September 23, 2025. Given that these shares have voting rights and the Class N common stock owned by the Company do not, management reduced the value to $0.034 per share of Class N common stock, reflecting the 3-5% premium typically attributed to voting rights, valuing the shares at $3,740. The Finch Pharma shares were received for no consideration, and accordingly, the Company did not increase its investment in Zylö for such shares.

 

The valuations reflect a probability-weighted present value of expected future investment returns considering certain possible outcomes and the rights of each class of Zylö’s, Atticus Pharma’s, and Finch’s equity. The future values of the common stock under the various outcomes are discounted back to the valuation date at a risk-adjusted discount rate and probability weighted to determine the value for the Class B common stock. Significant unobservable inputs in the valuation include (i) probabilities of each scenario, (ii) timing of occurrence, (iii) future valuation; and (iv) the risk-adjusted discount rate.

 

The consolidated investment in Zylö was valued at $36,819 and $36,819 as of September 30, 2026 and December 31, 2025, respectively.

 

18

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

NOTE 7 – PREPAID EXPENSES AND OTHER ASSETS

 

As of September 30, 2026 and December 31, 2025, prepaid expenses and other assets consisted of the following: 

 

    As of
September 30,
2026
    As of
December 31,
2025
 
Prepaid clinical trial expenses   $ 974,635     $ 987,605  
Prepaid stock-based compensation     317,819       -  
Prepaid insurance     85,815       40,008  
R&D credit receivable     7,590       11,707  
Other prepaid expenses and other assets     417,473       26,648  
Total     1,803,332       1,065,968  
Prepaid expenses and other assets, current portion     (836,197 )     (366,548 )
Prepaid expenses and other assets, long-term portion   $ 967,135     $ 699,420  

 

NOTE 8 – EQUITY SECURITIES WITHOUT READILY DETERMINABLE FAIR VALUES

 

On July 14, 2026, the Company entered into a Simple Agreement for Future Equity (“SAFE”) with Placeve Inc., a Delaware company (“Placeve”). In connection with the SAFE, the Company made an initial investment of $250,000 in Placeve for the right to certain shares of Placeve. If there is an equity financing in Placeve, before the termination of the SAFE, on the initial closing of such equity financing, the SAFE will automatically convert into the number of shares of SAFE preferred stock equal to the purchase amount divided by the discount price, which equals the lowest price per share of preferred stock sold in the equity financing multiplied by the discount rate of 90%. The investment is carried at cost, less any impairment, and adjusted up or down for observable price changes in orderly transactions for an identical or similar investment of the same issuer. Any such adjustments are recognized in other income (expense), net, in the condensed consolidated statements of operations. In October 2026, Placeve’s board and stockholders approved its dissolution, and Placeve notified the Company that it expects to distribute approximately $100,000 to the Company in full settlement of the SAFE. Because this information provided evidence of conditions that existed at September 30, 2026, the Company recorded an impairment loss of $150,000 for the three and nine months ended September 30, 2026, reducing the carrying amount to its estimated fair value of $100,000. The $100,000 cash distribution was received in October 2026. As of September 30, 2026, the $100,000 carrying amount is classified as a current asset because it is expected to be realized in cash within twelve months and is included in prepaid expenses and other assets on the accompanying unaudited condensed consolidated balance sheet.

 

NOTE 9 – INTANGIBLE ASSETS AND GOODWILL

 

As a result of the acquisition of Tracer, on September 21, 2026, there was a $799,640 increase in the gross intangible assets made up of $208,846 of finite lived intangible assets and $590,794 of goodwill (See Note 3). The increase in gross finite lived intangible assets was associated with customer relationships and a trade name that have finite lives. The Company shall begin amortization of the finite lived intangible assets in the fourth quarter of 2026.

 

As of September 30, 2026, intangible assets subject to amortization amounted to $208,846 consisting of the following:

 

    Amortization period (years)     Gross Amount     Accumulated Amortization     Net Finite Intangible Assets  
Customer relationships     15     $ 159,259     $       -     $ 159,259  
Trade name     7       49,587       -       49,587  
            $ 208,846     $ -     $ 208,846  

 

19

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Amortization of the intangible assets attributable to future periods is as follows:

 

Year ending September 30:   Amount  
2027   $ 17,701  
2028     17,701  
2029     17,701  
2030     17,701  
2031     17,701  
Thereafter     120,341  
    $ 208,846  

 

On September 30, 2026, goodwill consisted of the following:

 

    Useful Life     September 30,
2026
 
Goodwill     -     $ 590,794  
            $ 590,794  

 

NOTE 10 – STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is authorized to issue up to 10,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, and shall have such designations, preferences and relative, participating, optional or other special rights and qualifications, limitations or restrictions thereof as shall be determined at the time of issuance by the Company’s board of directors without further action by the Company’s shareholders. As of September 30, 2026 and December 31, 2025, 5,000,000 shares of the Company’s preferred stock have been designated as Series A Convertible Preferred Stock, 2,000,000 shares of the Company’s preferred stock have been designated as Series B Preferred Stock, and 3,000,000 shares of the Company’s preferred stock remain undesignated.

 

Series A Convertible Preferred Stock

 

The shares of Series A Convertible Preferred Stock, par value $0.0001 per share, are not mandatorily redeemable and do not embody an unconditional obligation to settle in a variable number of equity shares. As such, the shares of Series A Convertible Preferred Stock are classified as permanent equity on the condensed consolidated balance sheets. The holders’ contingent redemption right in the event of certain deemed liquidation events does not preclude permanent equity classification. Further, the shares of Series A Convertible Preferred Stock are considered an equity-like host for purposes of assessing embedded derivative features for potential bifurcation. The embedded conversion feature is considered to be clearly and closely related to the associated convertible preferred stock host instrument and therefore was not bifurcated from the equity host. As of September 30, 2026 and December 31, 2025, no shares of Series A Convertible Preferred Stock were issued and outstanding.

  

Series B Preferred Stock

 

On November 2, 2022, the Company filed a Certificate of Designation of the Series B Preferred Stock (the “Certificate of Designation”) with the Secretary of State of the State of Nevada to create a new class of Series B Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock”). The Certificate of Designation designated 2,000,000 shares of authorized preferred stock as Series B Preferred Stock. The Series B Preferred Stock was not entitled to receive dividends or any other distributions. The Series B Preferred Stock was entitled to ten votes per share and voted together with the Company’s issued and outstanding shares of common stock as a single class exclusively with respect to a proposal to increase the number of shares of common stock that the Company was authorized to issue, together with any ancillary or administrative matters necessary or advisable in connection with the implementation of such increase. The Series B Preferred Stock had no rights as to any distribution or assets of the Company upon liquidation, bankruptcy, reorganization, merger, acquisition, sale, dissolution or winding up of the Company. As of September 30, 2026 and December 31, 2025, no shares of Series B Preferred Stock were issued and outstanding.

 

20

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Common Shares

 

2025

 

On January 7, 2025, the Company issued 3,750,000 common shares in connection with the exercise of the 3,750,000 April 2024 Inducement Warrants (as defined below) for cash proceeds of $5,625,000. See Warrants section below.

 

On January 13, 2025, the Company entered into a Patent Application Acquisition Agreement with Med30 LLC (the “Seller”), whereby the Seller sold, conveyed, assigned and transferred to the Company all of Seller’s right, title, and interest in and to certain patent applications and associated rights, subject to the terms and conditions set forth in such agreement for a cash payment of $400,000 and the issuance of 450,000 shares of the Company’s common stock. These common shares were valued at $850,500, or $1.89 per share, on the measurement date based on the quoted closing price of the Company’s common stock (see Note 5).

 

On November 8, 2024, the Company entered into the ATM Agreement with Wainwright under which the Company could offer and sell shares of its common stock through Wainwright as the sales agent pursuant to the Company’s effective shelf registration statement on Form S-3 (File No. 333-272620), including an accompanying base prospectus and a prospectus supplement dated November 8, 2024. Sales of shares of the Company’s common stock through Wainwright, if any, will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended. Wainwright will use commercially reasonable efforts to sell shares of the Company’s common stock from time to time, based on instructions from the Company (including any price, time or size limits or other parameters or conditions the Company may impose). The Company will pay Wainwright a commission equal to 3.0% of the aggregate gross proceeds from the sales of shares of the Company’s common stock sold through Wainwright under the ATM Agreement and will also reimburse Wainwright for certain specified expenses in connection with the ATM Agreement. The aggregate market value of the shares of common stock eligible for sale is currently $5,257,000. From November 8, 2024 through November 12, 2026, the Company sold 9,825,684 shares of common stock through the ATM Agreement which resulted in approximately $13.56 million in gross proceeds.

  

During the three months ended March 31, 2025, pursuant to the ATM Agreement, the Company issued an aggregate of 927,968 shares of its common stock for net proceeds of $1,441,964. During the three months ended June 30, 2025, pursuant to the ATM Agreement, the Company issued an aggregate of 63,312 shares of its common stock for net proceeds of $66,101. During the three months ended September 30, 2025, pursuant to the ATM Agreement, the Company issued an aggregate of 1,404,339 shares of its common stock for net proceeds of $2,003,491.

 

On August 28, 2025, the Company issued 800,000 shares of common stock to the Company’s Chief Executive Officer as compensation under its equity incentive plan. The total grant-date fair value of the awards was $968,000, which was recognized as compensation expense in the unaudited condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2025. In connection with the issuance, the Company withheld 310,744 shares with a total fair value of $376,000 to satisfy employees’ minimum statutory tax withholding obligations. As a result, the Company issued a net of 489,256 shares to its Chief Executive Officer. The shares withheld for taxes are accounted for as a repurchase of shares and do not reduce the amount of compensation expense recognized. The Company remitted the related cash obligation to taxing authorities during the period. The Company’s policy is to allow net-share settlement of equity awards for tax withholding purposes. Cash paid to tax authorities in connection with such share withholding arrangements is classified as a financing activity in the unaudited condensed consolidated statements of cash flows, in accordance with ASC 718-20-45. The following table summarizes share activity related to stock compensation during the three and nine months ended September 30, 2025:

 

Activity   Number of
Shares
 
Shares granted (gross)     800,000  
Less: shares withheld for taxes     (310,744 )
Net shares issued to employee     489,256  

 

21

 

  

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

2026

 

During the three months ended March 31, 2026, pursuant to the ATM Agreement, the Company issued an aggregate of 756,187 shares of its common stock for net proceeds of $701,484.

 

During the three months ended June 30, 2026, pursuant to the ATM Agreement, the Company issued an aggregate of 3,436,991 shares of its common stock for net proceeds of $5,145,579.

 

During the three months ended September 30, 2026, pursuant to the ATM Agreement, the Company issued an aggregate of 1,712,947 shares of its common stock for net proceeds of $1,938,594.

 

On April 1, 2026, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which the Company sold to such investors 2,857,144 shares of common stock of the Company at a purchase price of $0.70 per share of common stock. For each share of common stock purchased by the investors, the Company, in a private placement pursuant to the Purchase Agreement, concurrently issued to such investors warrants to purchase one share of common stock at an exercise price of $0.85 per share (the “April 2026 Warrants”). The April 2026 Warrants are exercisable six months from the date of issuance (the “Initial Exercise Date”) for a period of five years from the Initial Exercise Date. Gross proceeds were approximately $2,000,000, and the Company received net proceeds of $1,611,880, after deducting placement agent’s fees and other offering expenses paid by the Company of $388,121. Additionally, in connection with the offering, the Company issued warrants (the “April Placement Agent Warrants”) to the designees of the placement agent, to purchase up to 142,857 shares of common stock. The April Placement Agent Warrants are immediately exercisable at an exercise price of $0.875 per share and expire on April 1, 2031.

 

On May 14, 2026, the Company issued 500,000 shares of its common stock for business development and consulting services rendered and to be rendered. These shares were valued at $332,950, or $0.67 per common share, based on the closing price of the Company’s common stock on the measurement date, and will be amortized into stock-based consulting fees over the estimated term of the agreement of one year. In connection with the issuance of these shares, during the three and nine months ended September 30, 2026, the Company recorded stock-based professional fees of $83,237 and $124,856, respectively, and as of September 30, 2026, the Company recorded prepaid expenses of $208,094, which will be amortized over the remaining service period through May 14, 2027.

 

On June 10, 2026, the Company issued an aggregate of 120,000 shares of its common stock for business development and consulting services rendered and to be rendered. These shares were valued at $159,600, or $1.33 per common share, based on the closing price of the Company’s common stock on the measurement date, and will be amortized into stock-based consulting fees over the term of the agreement of one year. In connection with the issuance of these shares, during the three and nine months ended September 30, 2026, the Company recorded stock-based professional fees of $39,900 and $49,875, respectively, and as of September 30, 2026, the Company recorded prepaid expenses of $109,725, which will be amortized over the remaining service period through June 10, 2027.

 

Warrants

 

On March 27, 2024, as an inducement to exercise certain warrants, the Company issued new unregistered warrants to purchase up to 3,750,000 shares of the Company’s common stock at an exercise price of $1.50 per share (the “April 2024 Inducement Warrants”). On January 7, 2025, the Company issued 3,750,000 common shares in connection with the exercise of the 3,750,000 April 2024 Inducement Warrants for cash proceeds of $5,625,000.

 

On June 4, 2025, pursuant to a six-month marketing service agreement, the Company issued warrants to purchase up to 300,000 shares of the Company’s common stock at an exercise price of $1.00 per share to a consultant of the Company for investor relations services. The warrants expire on June 4, 2027. The grant date fair value of these warrants was $333,150, which was recorded as a prepaid expense, and was expensed as stock-based professional fees over the term of the marketing service agreement. In connection with this warrant, during the three and nine months ended September 30, 2025, the Company recorded stock-based professional fees of $166,575 and $222,100, respectively.

 

On April 2, 2026, in connection with the Purchase Agreement, the Company issued the investors the April 2026 Warrants to purchase up to 2,857,144 shares of common stock at an exercise price of $0.85 per share. The April 2026 Warrants are exercisable six months from the date of issuance for a period of five years from the Initial Exercise Date. Additionally, in connection with the offering, the Company issued April Placement Agent Warrants to the designees of the placement agent to purchase up to 142,857 shares of common stock. The April Placement Agent Warrants are immediately exercisable at an exercise price of $0.875 per share and expire on April 1, 2031.

 

22

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

The measurement of fair value of the April 2026 Warrants and April Placement Agent Warrants was determined utilizing a Black-Scholes model considering all relevant assumptions current on April 2, 2026, the date of issuance. The grant date fair value of these April 2026 Warrants and April Placement Agent Warrants was estimated to be $1,389,829 on April 2, 2026 and was reflected within additional paid-in capital as the April 2026 Warrants and April Placement Agent Warrants were determined to be equity classified.

 

The fair value of the April 2026 Warrants, April Placement Agent Warrants and other warrants were estimated using the Black-Scholes option-pricing model with the following assumptions: 

 

    April 2, 2026     June 4, 2025  
Exercise price     $0.85 to $0.875     $ 1.00  
Term (years)     5.0 to 5.5       2.0  
Expected stock price volatility     120.35 %     129.68 %
Risk-free rate of interest     3.94 %     3.87 %

 

A summary of warrant activity for the nine months ended September 30, 2026 is as follows:

 

    Number of
Warrants
    Weighted
Average
Exercise
Price
    Total
Intrinsic
Value
    Weighted
Average
Remaining
Contractual Life
(in years)
 
Outstanding as of December 31, 2025     1,740,752     $ 4.38     $ -       2.37  
Granted     3,000,001       0.85       -       -  
Expired     (56,932 )     56.25       -       -  
Outstanding as of September 30, 2026     4,683,821       1.49       -       3.81  
Warrants exercisable as of September 30, 2026     1,826,677     $ 2.49     $ -       1.93  

 

The Company has determined that the warrants should be accounted for as a component of stockholders’ equity.

 

2018 Equity Incentive Plan

 

On May 4, 2018, the Company’s board of directors adopted the Rocket One Inc. 2018 Equity Incentive Plan (the “2018 Plan”) initially reserving 40,000 shares of the Company’s common stock for issuance thereunder. The 2018 Plan became effective on May 14, 2018 upon written approval of the 2018 Plan by shareholders holding a majority of the Company’s voting capital. The 2018 Plan provides that on the first day of each fiscal year commencing on January 1, 2019, the share limit (as defined in the 2018 Plan) and the ISO Limit (as defined in the 2018 Plan) shall automatically be increased by that number of shares equal to the lowest of (i) 10,000 shares of common stock, (ii) 5% of the number of shares of the Company’s common stock outstanding as of such date and (iii) an amount determined by the compensation committee of the board of directors (the “Committee”).

 

The Committee increased the number of shares reserved pursuant to the 2018 Plan by 26,878 shares effective as of January 1, 2021, such that as of January 1, 2021, the Company had an aggregate of 66,878 shares of common stock reserved for issuance pursuant to the 2018 Plan. On June 24, 2021, at the annual meeting of shareholders, shareholders of the Company approved an amendment to the 2018 Plan to further increase the number of shares reserved for issuance thereunder from 66,878 shares to 146,878 shares. On February 2, 2022, the Committee further increased the number of shares reserved for issuance under the 2018 Plan from 146,878 shares to 156,878 shares. On January 11, 2023, the Committee further increased the number of shares reserved for issuance under the 2018 Plan from 156,878 shares to 166,878 shares. On January 4, 2024, the Committee further increased the number of shares reserved for issuance under the 2018 Plan from 166,878 shares to 176,878 shares. On January 6, 2025, the Committee further increased the number of shares reserved for issuance under the 2018 plan from 176,878 shares to 186,878 shares. On January 5, 2026, the Committee further increased the number of shares reserved for issuance under the 2018 plan from 186,878 shares to 196,878 shares. As of September 30, 2026, there were 10,738 shares of Company common stock available for grant under the 2018 Plan.

 

23

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

2022 Equity Incentive Plan

 

On March 24, 2022, the Company’s board of directors adopted the Rocket One Inc. 2022 Omnibus Equity Incentive Plan (the “2022 Plan”) initially reserving 96,000 shares of the Company’s common stock for issuance thereunder. The 2022 Plan became effective on June 23, 2022 upon approval of the 2022 Plan by the Company’s shareholders at the Company’s annual meeting of shareholders.

 

On June 2, 2023, the Company’s board of directors approved the Rocket One Inc. Amended and Restated 2022 Omnibus Equity Incentive Plan (the “Amended and Restated 2022 Plan”) which, among other things, increased the number of shares reserved under the plan by 495,317 shares, which Amended and Restated 2022 Plan was approved by stockholders on August 18, 2023.

 

On May 15, 2024, the Committee recommended, and the board of directors approved an increase to the number of shares of common stock reserved for issuance under the Amended and Restated 2022 Plan by 500,000 shares from 591,317 shares to 1,091,317 shares (“2024 Increase”). The 2024 Increase was approved by shareholders of the Company on August 7, 2024.

 

On May 9, 2025, the Committee recommended, and the board of directors approved an increase to the number of shares of common stock reserved for issuance under the Amended and Restated 2022 Plan by 2,000,000 shares from 1,091,317 shares to 3,091,317 shares (“2025 Increase”). The 2025 Increase was approved by shareholders of the Company on August 5, 2025.

 

On September 22, 2026, the Committee recommended, and the board of directors approved an increase to the number of shares of common stock reserved for issuance under the Amended and Restated 2022 Plan by 3,250,000 shares from 3,091,317 shares to 6,341,317 shares (“2026 Increase”). The 2026 Increase remains subject to shareholder approval.

 

As of September 30, 2026, there were 31,317 shares of Company common stock available for grant under the Amended and Restated 2022 Plan.

 

Stock Options

 

On January 14, 2025, pursuant to the 2018 Plan, the Company issued options to the Company’s Chief Executive Officer to purchase up to 93,000 shares of the Company’s common stock at an exercise price of $1.55 per share. Additionally, on January 14, 2025, pursuant to and subject to the available number of shares reserved under the Amended and Restated 2022 Plan, the Company issued options to the Company’s Chief Executive Officer and an employee to purchase up to an aggregate of 77,000 shares of the Company’s common stock at an exercise price of $1.55 per share. The options vested immediately in full upon grant and expire on January 14, 2035. The aggregate grant date fair value of these options was $219,929, which was recorded as stock-based compensation in January 2025.

 

On May 26, 2026, pursuant to the 2022 Plan, the Company issued options to the Company’s Chief Executive Officer, employees and directors to purchase up to an aggregate of 1,050,000 shares of the Company’s common stock at an exercise price of $0.7083 per share. The options vested immediately in full upon grant and expire on May 26, 2036. The aggregate grant date fair value of these options was $625,485, which was recorded as stock-based compensation in May 2026.

  

The fair value of option grants was estimated on the date of grant using the Black-Scholes option-pricing model with the following assumptions:

 

    Nine Months Ended
September 30,
 
    2026     2025  
Exercise price   $ 0.7083     $ 1.55  
Term (years)     5.0       5.0  
Expected stock price volatility     120.79 %     118.32 %
Risk-free rate of interest     4.19 %     4.59 %

 

24

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

A summary of option activity under the Company’s equity incentive plans for the nine months ended September 30, 2026 is presented below:

 

    Number of
Shares
    Weighted
Average
Exercise
Price
    Total
Intrinsic
Value
    Weighted
Average
Remaining
Contractual
Life
(in years)
 
Outstanding as of December 31, 2025     1,260,362     $ 4.340     $ 111,250       8.2  
Employee options issued     1,050,000       0.71       -       -  
Expired     -       -       -       -  
Outstanding as of September 30, 2026     2,310,362     $ 2.69     $ 10,345       8.5  
Options vested and exercisable as of September 30, 2026     2,310,362     $ 2.69     $ 10,345       8.5  

 

A summary of stock options outstanding as of September 30, 2026 by price range is as follows:

 

    Options outstanding and exercisable  
Range of Exercise Prices   Number of
Shares
    Weighted
Average Remaining
Contractual
Life (in years)
    Weighted
Average Exercise
Price
 
Up to $2.59     2,233,000       8.6     $ 0.98  
$14.75 to $76.25     62,562       5.1     $ 32.95  
Above $76.25     14,800       3.3     $ 131.50  
Options outstanding and exercisable as of September 30, 2026     2,310,362       8.5     $ 2.69  

 

All stock compensation associated with the amortization of employee stock option expense was recorded as a component of general and administrative expenses in the unaudited condensed consolidated statements of operations and comprehensive loss.

 

Estimated future stock-based compensation expense relating to unvested stock options is $0.

  

Stock-Based Compensation

 

Stock-based compensation expense for the three and nine months ended September 30, 2026 and 2025 was as follows:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Employee stock option awards   $ —     $ —     $ 625,485     $ 219,929  
Employee restricted stock award     —       968,000       —       968,000  
Non-employee restricted stock awards     123,137       —       174,731       —  
Non-employee stock warrant awards     —       166,575       —       222,100  
    $ 123,137     $ 1,134,575     $ 800,216     $ 1,410,029  

 

25

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

For the three and nine months ended September 30, 2026 and 2025, the amount of stock-based compensation expense included within professional fees and general and administrative expenses was as follows:

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Research and development   $ -     $ -     $ -     $ -  
Professional fees     123,137       166,575       174,731       222,100  
General and administrative     -       968,000       625,485       1,187,929  
    $ 123,137     $ 1,134,575     $ 800,216     $ 1,410,029  

 

NOTE 11 – COMMITMENTS AND CONTINGENCIES

 

Office Leases

 

On December 9, 2024, the Company and the landlord entered into a lease agreement (the “December 2024 Lease”). Pursuant to the December 2024 Lease, effective December 20, 2024, the Company leased office space for a term of 14 months, expiring on February 28, 2026. Pursuant to the December 2024 Lease, the Company paid a monthly base rent of $2,732 from March 1, 2025 through December 31, 2025. Effective January 1, 2026, the Company entered into an amendment to the December 2024 Lease. Pursuant to the amendment to the December 2024 Lease, the Company renewed its lease for a one-year term expiring on December 31, 2026. ROU assets and obligations for leases with an initial term of 12 months or less are considered short term and are (a) not recognized in the condensed consolidated balance sheets and (b) recognized as an expense on a straight-line basis over the lease term.

 

Tracer leases incubator space from a community college at $540 per month, commencing June 1, 2026 and expiring on June 1, 2027, with two 12-month renewal options at Tracer’s option. Tracer elected not to recognize ROU assets and lease liabilities for leases with a term of 12 months or less. The Company concluded that it was not reasonably certain to exercise the extension options. The option periods are therefore excluded from the lease term and from the measurement of the ROU asset and lease liability.

 

The table below presents certain information related to the Company’s lease costs, which are included in general and administrative expenses in the accompanying unaudited condensed consolidated statements of operations and comprehensive loss: 

 

    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Operating lease expense   $ -     $ 7,136     $ 4,652     $ 21,675  
Short-term lease expense     3,920       7,620       16,010       18,995  
Total lease cost   $ 3,920     $ 14,756     $ 20,662     $ 40,670  

 

ROU asset for operating leases was recorded in the accompanying unaudited condensed consolidated balance sheets as follows:

 

    September 30,
2026
    December 31,
2025
 
Office lease ROU asset   $         -     $ 31,075  
Less accumulated amortization     -       (26,423 )
Total ROU asset, net   $ -     $ 4,652  

 

26

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Operating lease liability for operating leases was recorded in the accompanying unaudited condensed consolidated balance sheets as follows:

 

    September 30,
2026
    December 31,
2025
 
Current portion of operating lease liability   $      —     $ 5,678  
Long-term portion of operating lease liability     —       —  
Total operating lease liability   $ —     $ 5,678  

 

Supplemental cash flow information related to the Company’s leases for the nine months ended September 30, 2026 was as follows:

 

Cash paid for amounts included in the measurement of lease liabilities:      
Operating cash flows for operating leases   $ 5,678  

 

NOTE 12 – SEGMENT REPORTING

 

Through March 31, 2026, the Company operated as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. During the three months ended June 30, 2026, the Company began the process of transitioning primarily into an AI semiconductor infrastructure company building nanomagnetic and spintronic computing for ultra-low-power AI, resilient edge, defense, and space. Accordingly, beginning in the second quarter of 2026, the Company began operating in two reportable segments which consist of (1) a clinical-stage biopharmaceutical company, herein known as the “Biopharmaceutical” segment, and (2) an AI semiconductor infrastructure and other technologies company, herein known as the “AI Infrastructure and Technologies” segment. The AI Infrastructure and Technologies segment includes Tracer. The Company has determined that these reportable segments are strategic business units that offer different products. These reportable segments shall be managed separately based on the fundamental differences in their operations.

 

Through September 30, 2026, corporate and administrative amounts have been allocated to the Biopharmaceutical segment since substantially all of the Company’s operations are attributable to this segment.

 

The Company’s Chief Operating Decision Maker (“CODM”) is its Chief Executive Officer. The decisions concerning the allocation of the Company’s resources are made by the CODM with oversight by the Board. The CODM evaluates the performance of each segment and makes decisions concerning the allocation of resources based upon segment operating profit (loss), generally defined as income or loss before interest expense and income taxes. The CODM assesses segment performance by using each segment’s loss from operations and considers budget-to-actual variances on a periodic basis (at least quarterly) when making decisions about operational planning, including whether to invest resources into the segments or into other parts of the Company. Segment assets are reviewed by the Company’s CODM and are disclosed below. The accounting policies of the Biopharmaceutical segment and the AI Infrastructure and Technologies segment are the same as those described in Note 2 of these unaudited condensed consolidated financial statements.

 

27

 

  

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Information with respect to these reportable business segments for the three and nine months ended September 30, 2026 and 2025 was as follows:

 

Three Months Ended September 30, 2026

 

    Biopharmaceutical
segment
    AI
Infrastructure
and
Technologies
segment
    Consolidated  
Net revenues   $ -     $ 35     $ 35  
                         
Operating expenses     2,331,820       197,558       2,529,378  
Depreciation and amortization     -       -       -  
Loss from operations     (2,331,820 )     (197,523 )     (2,529,343 )
Interest expense     -       -       -  
Other income     150       -       150  
Impairment loss on equity securities without readily determinable fair value     (150,000 )     -       (150,000 )
Loss before provision for income taxes     (2,481,670 )     (197,523 )     (2,679,193 )
Provision for income taxes     -       -       -  
Net loss   $ (2,481,670 )   $ (197,523 )   $ (2,679,193 )

 

Three Months Ended September 30, 2025

 

    Biopharmaceutical
segment
    AI
Infrastructure
and
Technologies
segment
    Consolidated  
Net revenues   $ -     $ -     $ -  
                         
Operating expenses     4,080,664                   -       4,080,664  
Depreciation and amortization     -       -       -  
Loss from operations     (4,080,664 )     -       (4,080,664 )
Interest expense     -       -       -  
Other expenses, net     (25,137 )     -       (25,137 )
Loss before provision for income taxes     (4,105,801 )     -       (4,105,801 )
Provision for income taxes     -       -       -  
Net loss   $ (4,105,801 )   $ -     $ (4,105,801 )

 

Nine Months Ended September 30, 2026

 

    Biopharmaceutical
segment
    AI
Infrastructure
and
Technologies
segment
    Consolidated  
Net revenues   $ -     $ 35     $ 35  
                         
Operating expenses     8,539,112       473,515       9,012,627  
Depreciation and amortization     -       -       -  
Loss from operations     (8,539,112 )     (473,480 )     (9,012,592 )
Interest expense     -       -       -  
Realized loss on crypto assets     (44,165 )     -       (44,165 )
Other income     448       -       448  
Impairment loss on equity securities without readily determinable fair value     (150,000 )     -       (150,000 )
Loss before provision for income taxes     (8,732,829 )     (473,480 )     (9,206,309 )
Provision for income taxes     -       -       -  
Net loss   $ (8,732,829 )   $ (473,480 )   $ (9,206,309 )

 

28

 

 

ROCKET ONE INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

September 30, 2026

 

Nine Months Ended September 30, 2025

 

    Biopharmaceutical
segment
    AI
Infrastructure
and
Technologies
segment
    Consolidated  
Net revenues   $ -     $          -     $ -  
                         
Operating expenses     9,756,330       -       9,756,330  
Depreciation and amortization     -       -       -  
Loss from operations     (9,756,330 )     -       (9,756,330 )
Interest expense     -       -       -  
Other expenses, net     (24,783 )     -       (24,783 )
Loss before provision for income taxes     (9,781,113 )     -       (9,781,113 )
Provision for income taxes     -       -       -  
Net loss   $ (9,781,113 )   $ -     $ (9,781,113 )

 

Total assets by segment on September 30, 2026 and December 31, 2025 were as follows:

 

    September 30,
2026
    December 31,
2025
 
Biopharmaceutical segment   $ 7,843,049     $ 7,603,444  
AI Infrastructure and Technologies segment     817,320       -  
    $ 8,660,369     $ 7,603,444  

  

NOTE 13 – SUBSEQUENT EVENTS

 

The Company has evaluated subsequent events and transactions that occurred up to the date the unaudited condensed consolidated financial statements were issued. Based upon this review, except as noted below, the Company did not identify any subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements.

 

In October 2026, the Company received a $100,000 cash distribution related to its equity securities without readily determinable fair value (see Note 8).

 

29

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q. In addition to historical information, this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results may differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 as may be amended, supplemented or superseded from time to time by other reports we file with the SEC. All amounts in this report are in U.S. dollars, unless otherwise noted.

 

In May 2026, we announced a strategic repositioning pursuant to which we are now pursuing opportunities in artificial intelligence (“AI”) infrastructure, next-generation semiconductor technologies, and ultra-low-power AI computing. Specifically, we are an AI semiconductor infrastructure company building nanomagnetic and spintronic computing for ultra-low-power AI, resilient edge, defense, and space. We are also focused on developing (i) a nanomagnetic matrix multiplier; (ii) Skyrmion Spintronic memory; and (iii) Swarm Stage AI.

 

Additionally, we also continue to have preclinical and clinical assets that will be developed under our wholly owned subsidiary, Hoth Therapeutics, Inc., for (i) a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); (ii) a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); (iii) a treatment for obesity, and obesity-related diseases and conditions (HT-VA); and (iv) a treatment for Alzheimer’s Disease (HT-ALZ).

  

On September 18, 2026, the Company entered into a definitive Membership Interest Purchase Agreement to acquire all of the issued and outstanding membership interests of Tracer Drone Technologies, LLC (“Tracer”), a New Jersey-based provider of drone hardware, software, training, maintenance and managed services. On September 21, 2026, the Company closed on the Membership Interest Purchase Agreement and acquired 100% of Tracer’s membership interests. The acquisition of Tracer adds an established, revenue-generating commercial platform and combines operating drone capabilities with the Company’s broader AI, space, and defense technology strategy.

 

Results of Operations

 

Comparison of Our Results of Operations for the Three Months Ended September 30, 2026 and 2025

 

Revenues

 

For the three months ended September 30, 2026, revenues were $35, which related to the acquisition of Tracer on September 21, 2026. We did not record any revenues during the three months ended September 30, 2025.

 

Operating Costs and Expenses

 

Research and Development Expenses

 

For the three months ended September 30, 2026, research and development expenses were approximately $1,123,000. Specifically, during the three months ended September 30, 2026, our research and development costs consisted primarily of the following costs for each of our key research and development projects: (i) HT-001, approximately $979,000 related to manufacturing and clinical activities; and (ii) HT-VA approximately $35,000 related to preclinical studies. In addition to the foregoing, we also incurred fees of approximately $79,000 payable to members of our scientific advisory board for services, and $30,000 in licensing fees. 

 

30

 

 

For the three months ended September 30, 2025, research and development expenses were approximately $1,633,000. Specifically, during the three months ended September 30, 2025, our research and development costs consisted primarily of the following costs for each of our key research and development projects: (i) HT-001, approximately $1,477,000 related to manufacturing and clinical activities; and (ii) HT-KIT, approximately $125,000 related to manufacturing and preclinical activities. In addition to the foregoing, we also incurred fees of approximately $31,000 payable to members of our scientific advisory board for services. 

 

We expect our research and development activities to continue to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following:

 

● employee-related expenses, which include salaries and benefits, and rent expenses;

 

● fees related to in-licensed products and technology;

 

● expenses incurred under agreements with contract research organizations (“CROs”), investigative sites and consultants that conduct our clinical trials and a substantial portion of our technology and development activities;

 

● the cost of acquiring and manufacturing materials; and

 

● costs associated with development activities and regulatory approvals.

 

General and Administrative Expenses

 

For the three months ended September 30, 2026, general and administrative expenses amounted to approximately $1,406,000 as compared to $2,447,000 for the three months ended September 30, 2025, a decrease of $1,041,000, or 42.5%. For the three months ended September 30, 2026 and 2025, general and administrative expenses consisted of the following (rounded to the nearest $1,000):

 

    Three Months Ended
September 30,
 
    2026     2025  
Compensation and related expenses   $ 403,000     $ 1,376,000  
Professional and consulting expenses     757,000       894,000  
Rent expense     4,000       15,000  
Other general and administrative expenses     242,000       162,000  
Total   $ 1,406,000     $ 2,447,000  

 

During the three months ended September 30, 2026, the decrease in general and administrative expenses of approximately $1,041,000 was primarily attributed to (1) a decrease in compensation and related expenses of $973,000 primarily attributable to a decrease in stock-based compensation of approximately $968,000 in connection with the issuance of common stock for services during the three months ended September 30, 2025 as compared to none during the three months ended September 30, 2026, and a decrease in other compensation and related expenses of $5,000, (2) a decrease in professional and consulting expenses of approximately $137,000 which was primarily attributable to a decrease in legal and consulting fees of approximately $103,000, an increase in accounting fees of approximately $19,000, a decrease in stock-based professional fees of $43,000, and a decrease in directors’ fees of approximately $6,000, (3) a decrease in rent expense of $11,000 and (4) an increase in other general and administrative expenses of $80,000, primarily attributable to an increase in patent expenses of $54,000, an increase in travel expense of $12,000, and an increase in other general and administrative expenses of $14,000.

 

31

 

 

We anticipate that our general and administrative expenses will continue to increase in future periods, reflecting continued and increasing costs associated with:

 

● support for our research and development activities;

 

● stock compensation granted to key employees and non-employees;

 

● support of business development activities; and

 

● increased professional fees and other costs associated with regulatory requirements that we are subject to.

 

Other Income (Expenses)

 

For the three months ended September 30, 2026 and 2025, other expenses, net was approximately $150,000 and $25,000, respectively. During the three months ended September 30, 2026, we recorded an impairment loss on equity securities without readily determinable fair value of $150,000. During the three months ended September 30, 2025, we recorded a realized loss on crypto assets of approximately $25,000.  

 

Net Loss

 

For the three months ended September 30, 2026 and 2025, we incurred a net loss of approximately $2,679,000, or $0.11 per common share (basic and diluted), and $4,106,000, or $0.30 per common share (basic and diluted), respectively.

 

Comparison of Our Results of Operations for the Nine Months Ended September 30, 2026 and 2025

 

Revenues

 

For the nine months ended September 30, 2026, revenues were $35, which related to the acquisition of Tracer on September 21, 2026. We did not record any revenues during the nine months ended September 30, 2025.

 

Operating Costs and Expenses

 

Research and Development Expenses

 

For the nine months ended September 30, 2026, research and development expenses were approximately $4,598,000. Specifically, during the nine months ended September 30, 2026, our research and development costs consisted primarily of the following costs for each of our key research and development projects: (i) HT-001, approximately $4,043,000 related to manufacturing and clinical activities; (ii) HT-KIT, approximately $13,000 related to manufacturing and preclinical activities; and (iii) HT-VA approximately $115,000 related to preclinical studies. In addition to the foregoing, we also incurred fees of approximately $139,000 payable to members of our scientific advisory board for services, $78,000 in licensing fees, and $210,000 of in-process research and development expenses in connection with the acquisition of software and other technologies.

 

32

 

 

For the nine months ended September 30, 2025, research and development expenses were approximately $4,632,000. Specifically, during the nine months ended September 30, 2025, our research and development costs consisted primarily of the following costs for each of our key research and development projects: (i) HT-001, approximately $2,585,000 related to manufacturing and clinical activities; (ii) HT-KIT, approximately $674,000 related to manufacturing and preclinical activities; and (iii) HT-ALZ, approximately $12,000 related to preclinical studies. In addition to the foregoing, we also incurred fees of approximately $100,000 payable to members of our scientific advisory board for services and recorded approximately $1,260,000 of in-process research and development expenses in connection with the acquisition of patent applications.

 

We expect our research and development activities to continue to increase as we develop our existing product candidates and potentially acquire new product candidates, reflecting increasing costs associated with the following:

 

● employee-related expenses, which include salaries and benefits, and rent expenses;

 

● fees related to in-licensed products and technology;

 

● expenses incurred under agreements with CROs, investigative sites and consultants that conduct our clinical trials and a substantial portion of our technology and development activities;

 

● the cost of acquiring and manufacturing materials; and

 

● costs associated with development activities and regulatory approvals.

 

General and Administrative Expenses

 

For the nine months ended September 30, 2026, general and administrative expenses amounted to approximately $4,415,000 as compared to $5,125,000 for the nine months ended September 30, 2025, a decrease of $710,000, or 13.8%. For the nine months ended September 30, 2026 and 2025, general and administrative expenses consisted of the following (rounded to the nearest $1,000):

 

    Nine Months Ended
September 30,
 
    2026     2025  
Compensation and related expenses   $ 1,822,000     $ 2,384,000  
Professional and consulting expenses     2,010,000       2,146,000  
Rent expense     21,000       41,000  
Other general and administrative expenses     562,000       554,000  
Total   $ 4,415,000     $ 5,125,000  

 

During the nine months ended September 30, 2026, the decrease in general and administrative expenses of approximately $710,000 was primarily attributed to (1) a decrease in compensation and related expenses of $562,000 attributable to an increase in stock-based compensation of approximately $406,000 in connection with the issuance of stock options, offset by a decrease in stock-based compensation of $968,000 in connection with the issuance of common stock for services during the three months ended September 30, 2025 as compared to none during the three months ended September 30, 2026, (2) a decrease in professional and consulting expenses of $136,000 attributable to a decrease in legal and other professional fees of $171,000 and a decrease in stock-based professional fees of $47,000, offset by an increase in accounting fees of $55,000 and an increase in director fees of $27,000, (3) a decrease in rent expense of $20,000, and (4) an increase in other general and administrative expenses of $8,000.

 

We anticipate that our general and administrative expenses will continue to increase in future periods, reflecting continued and increasing costs associated with:

 

● support for our research and development activities;

 

● stock compensation granted to key employees and non-employees;

 

● support of business development activities; and

 

● increased professional fees and other costs associated with regulatory requirements that we are subject to.

 

33

 

 

Other Income (Expenses), net

 

For the nine months ended September 30, 2026 and 2025, other income (expense), net was approximately $194,000 and $25,000, respectively. During the nine months ended September 30, 2026, we recorded an impairment loss on equity securities without readily determinable fair value of $150,000 and a realized loss of crypto assets of $44,000. During the nine months ended September 30, 2025, we recorded a realized loss on crypto assets of approximately $25,000.

 

Net Loss

 

For the nine months ended September 30, 2026 and 2025, we incurred a net loss of approximately $9,206,000, or $0.45 per common share (basic and diluted), and $9,781,000, or $0.74 per common share (basic and diluted), respectively.

 

Liquidity and Capital Resources 

 

Our unaudited condensed consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. We have incurred net losses and negative cash flows from operations since our inception and have historically funded our operations through the sale of equity securities. As of September 30, 2026, we had approximately $6,016,000 in cash and cash equivalents, working capital of approximately $5,620,000 and an accumulated deficit of approximately $82,086,000. Net cash used in operating activities was $8,804,000 and $7,654,000 for the nine months ended September 30, 2026 and 2025, respectively. We incurred net losses of approximately $9,206,000 and $9,781,000 for the nine months ended September 30, 2026 and 2025, respectively.

 

Our ability to continue as a going concern is dependent on our ability to raise additional capital to fund our research and development (“R&D”) activities and meet our obligations as they come due. We have incurred substantial operating losses since inception and expect to continue to incur significant operating losses for the foreseeable future as we continue to execute our longer-term business plans and development. We have not yet commercialized any products and have generated only minimal revenues through our recently acquired subsidiary, Tracer.

 

On August 6, 2026, we were notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that we are not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Under the Notification Letter, we have 180 calendar days, or until February 2, 2027, to regain compliance. If we do not not regain compliance by February 2, 2027, an additional 180 days may be granted to regain compliance, if we meet The Nasdaq Capital Market continued listing requirements (except for the bid price requirement) and notify Nasdaq in writing of our intention to cure the deficiency during the second compliance period. We intend to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance, including a reverse stock split.

 

We do not believe our current cash is sufficient to fund operations for at least one year from the date [these/the] unaudited condensed consolidated financial statements are issued. We will need to raise additional funding, through strategic relationships, public or private equity or debt financings, grants or other arrangements, to continue developing and seeking regulatory approvals for our current and future products and technologies. If funding is not available, or not available on terms acceptable to us, our current development plan and plans for expansion of our general and administrative infrastructure may be curtailed. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date our unaudited condensed consolidated financial statements are issued. Our unaudited condensed consolidated financial statements have been prepared on a going concern basis and do not include any adjustments to the amounts and classification of assets and liabilities that may be necessary in the event the Company can no longer continue as a going concern.

 

On November 8, 2024, we entered into an At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) under which we could offer and sell shares of our common stock through Wainwright. We have agreed to pay Wainwright a commission equal to 3.0% of the aggregate gross proceeds from the sales of shares of our stock sold through Wainwright under the ATM Agreement and will also reimburse Wainwright for certain specified expenses in connection with the ATM Agreement. The aggregate market value of the shares of common stock eligible for sale is currently $5,257,000. During the three and nine months ended September 30, 2026, the Company sold 1,712,947 and 5,906,125 shares of common stock, respectively, through the ATM Agreement which resulted in approximately $1,904,000 and $7,751,000 in net proceeds, respectively.

 

On April 1, 2026, we entered into a securities purchase agreement (the “Purchase Agreement”) with certain institutional investors, pursuant to which we agreed to sell to such investors 2,857,144 shares of common stock at a purchase price of $0.70 per share. We received gross proceeds of approximately $2,000,000, and net proceeds of approximately $1,611,880, after deducting placement agent’s fees and other offering expenses paid by us of $388,121 (see Note 10).

 

34

 

 

We have entered into certain license, sublicense, sponsored research and option agreements with third parties. Pursuant to such agreements, we may be required to make certain: (i) license maintenance fee payments; (ii) out-of-pocket expense payments, including, but not limited to, payments related to intellectual property and research related expenses; (iii) development and commercialization expense payments; (iv) annual and quarterly minimum payments; (v) diligence expense payments; and (vi) revenue interest payments. In addition, subject to the achievement of certain development and/or commercialization events, we may also be required to make certain: (i) minimum royalty payments, ranging from middle to high five figures, (ii) sales-based royalties and running royalties, ranging from low single digits to low double digits; and (iii) milestone payments, of up to approximately $29 million (if all milestones in all of our current agreements are achieved).

 

Cash Flows from Operating Activities

 

For the nine months ended September 30, 2026, net cash used in operating activities was approximately $8,804,000, which primarily resulted from a net loss of approximately $9,206,000, an increase in prepaid expenses and other current assets of approximately $319,000, a decrease in accounts payable and accrued expenses of approximately $273,000, offset by the add back of non-cash items such as approximately $44,000 of realized loss on crypto assets, $800,000 in stock-based compensation and professional fees, and an impairment loss on equity securities without readily determinable fair value of $150,000.

 

For the nine months ended September 30, 2025, net cash used in operating activities was approximately $7,654,000, which primarily resulted from a net loss of approximately $9,781,000, an increase in prepaid expenses and other current assets of approximately $357,000 and an increase in accounts payable and accrued expenses of approximately $196,000, offset by approximately $850,000 of non-cash research and development-acquired patent, $1,410,000 in stock-based compensation and professional fees, and unrealized loss on crypto assets of $25,000.

 

Cash Flows from Investing Activities

 

During the nine months ended September 30, 2026, the Company used cash in investing activities of $845,000, which consisted of net cash used for the acquisition of Tracer of $743,000 and cash used for an investment in equity securities without readily determinable fair value of $250,000, offset by cash proceeds received from the sale of crypto assets of approximately $147,000.

 

During the nine months ended September 30, 2025, the Company purchased $300,000 in crypto assets. 

 

Cash Flows from Financing Activities

 

For the nine months ended September 30, 2026, net cash provided by financing activities was approximately $9,420,000, which resulted from net proceeds from the issuance of common stock, net of offering costs, of approximately $7,751,000 and from net proceeds from the issuance of common stock and warrants, net of offering costs, of approximately $1,669,000, before deducting $57,171 of offering costs paid in 2025.

 

For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $8,761,000, which primarily resulted from net proceeds from the issuance of common stock, net of offering costs, of approximately $3,512,000 and proceeds from the exercise of warrants of $5,625,000, offset by the payment of taxes related to the net share settlement of an equity award of $376,000.

 

Our ultimate success is dependent on our ability to obtain additional financing and generate sufficient cash flow to meet our obligations on a timely basis. We will require significant amounts of capital to sustain operations, and we will need to make the investments we need to execute our longer-term business plan to support new technologies and help advance innovation. Absent generation of sufficient revenue from the execution of our long-term business plan, we will need to obtain debt or equity financing, especially if we experience downturns in our business that are more severe or longer than anticipated, or if we experience significant increases in expense levels resulting from being a publicly traded company or from operations. Such additional debt or equity financing may not be available to us on favorable terms, if at all.

 

We plan to pursue our plans with respect to the research and development of our technology products, as well as our pre-clinical products, which will require resources beyond those that we currently have, ultimately requiring additional capital from third-party sources. We currently generate minimal revenues through our recently acquired subsidiary, Tracer.

 

35

 

 

Critical Accounting Estimates

 

The preparation of consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts and related disclosures in the financial statements. Management considers an accounting estimate to be critical if:

 

● it requires assumptions to be made that were uncertain at the time the estimate was made; and

 

● changes in the estimate or different estimates that could have been selected could have a material impact on our results of operations or financial condition.

 

While we base our estimates and judgments on our experience and on various other factors that we believe to be reasonable under the circumstances, actual results could differ from those estimates and the differences could be material.

 

See Note 2 to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q for an additional discussion of our significant accounting policies.

 

Business Acquisition

 

The Company accounted for its business acquisition using the acquisition method of accounting where the assets acquired and liabilities assumed are recognized based on their respective estimated fair values. Identifiable intangible assets acquired are recorded at their estimated fair values, and the excess of the purchase price over the fair value of the net assets acquired, including identifiable intangible assets, is recorded as goodwill. Determining the fair value of certain acquired assets and liabilities was subjective in nature and often involves the use of significant estimates and assumptions, including, but not limited to, the selection of appropriate valuation methodology, projected revenue, expenses, and cash flows, weighted average cost of capital, discount rates, and estimates of terminal values. The business acquisition was included in the Company’s condensed consolidated financial statements as of the date of the acquisition.

 

Stock-based compensation

 

The Company accounts for stock-based payment awards exchanged for services at the estimated grant date fair value of the award. Stock options issued under the Company’s long-term incentive plans are granted with an exercise price equal to no less than the market price of the Company’s stock at the date of grant and expire up to ten years from the date of grant. Options are generally issued fully vested. The Company accounts for forfeited awards as they occur.

 

The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model and the assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment.

 

Expected Term - The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.

 

Expected Volatility - The Company computes stock price volatility over expected terms based on its historical common stock trading prices.

 

Risk-Free Interest Rate - The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.

 

Expected Dividend - The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models.

 

The Company grants restricted stock awards under its equity incentive plan. Restricted stock awards are granted to employees and non-employees. The restricted stock awards are measured based on the grant-date fair value. In general, the restricted stock awards vest over a service period of zero to three years. Stock-based compensation expense is generally recognized based on the straight-line basis over the requisite service period and forfeitures are accounted for as they occur.

 

The Company has issued warrants to non-employees. The warrants are measured based on the grant-date fair value. In general, the warrants vest over a term of zero to ten years. Stock-based compensation expense is generally recognized based on the straight-line basis over the vesting term.

 

36

 

 

Recently Adopted Accounting Pronouncements

 

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”) amending ASC 326, Credit Losses, which provides a practical expedient for all entities in developing reasonable and supportable forecasts as part of estimating expected credit losses to assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The amendments in ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods, with early adoption permitted. The Company adopted ASU 2025-05 on January 1, 2026, and the adoption did not have a material impact on the Company’s unaudited condensed consolidated financial statements.

 

Recently Issued Accounting Standards Not Yet Effective or Adopted

 

In November 2024, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), which requires entities to provide more detailed disaggregation of expenses in the income statement, focusing on the nature of the expenses rather than their function. The new disclosures will require entities to separately present expenses for significant line items, including, but not limited to, depreciation, amortization, and employee compensation. Entities will also be required to provide a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively, disclose the total amount of selling expenses and, in annual reporting periods, provide a definition of what constitutes selling expenses. This pronouncement is effective for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. The Company does not expect the adoption of this new guidance to have a material impact on its unaudited condensed consolidated financial statements.

 

In December 2025, the FASB issued ASU 2025-11, Interim Reporting (Topic 270), Narrow-Scope Improvements, to provide clarity about the current requirements, rather than evaluate whether to expand or reduce interim disclosure requirements. The amendments in ASU 2025-11 result in a comprehensive list of interim disclosures that are required by GAAP. The amendments in ASU 2025-11 also include a disclosure principle that requires entities to disclose events since the end of the last annual reporting period that have a material impact on the entity. The amendments in ASU 2025-11 are effective for interim reporting periods within annual reporting periods beginning after December 15, 2027 and early adoption is permitted. The amendments in ASU 2025-11 can be applied either prospectively or retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the disclosure impact that ASU 2025-11 may have on its financial statement presentation and disclosures.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

The Company is not required to provide the information required by this Item as it is a “smaller reporting company,” as defined in Rule 12b-2 of the Exchange Act.

 

ITEM 4. CONTROLS AND PROCEDURES

 

As required by Rule 13a-15(b) of the Exchange Act, our management, with the participation of our principal executive officer and principal financial officer, has evaluated as of the end of the period covered by this report, the effectiveness of our disclosure controls and procedures. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files under the Exchange Act is accumulated and communicated to a company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.  Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, our disclosure controls and procedures were effective to reasonably ensure that information required to be disclosed and filed under the Exchange Act is recorded, processed, summarized and reported within the time periods specified, and that management will be timely alerted to material information required to be included in our periodic reports filed with the SEC.

 

Changes in Internal Control Over Financial Reporting

 

There have been no changes in our internal control over financial reporting that occurred during our last fiscal quarter ended September 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

37

 

 

PART II – OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

From time to time, we may be subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings and we are not aware of any pending or threatened legal proceeding against us that we believe could have a material adverse effect on our business, operating results, cash flows or financial condition.

 

ITEM 1A. RISK FACTORS

 

Risk factors that affect our business and financial results are discussed in Part I, Item 1A “Risk Factors,” in our Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 27, 2026 (“Annual Report”), as subsequently updated, amended or superseded by our other filings made with the SEC. Except as otherwise set forth herein, there have been no material changes in our risk factors from those previously disclosed in our Annual Report and other filings made with the SEC. You should carefully consider the risks in our filings with the SEC which could materially affect our business, financial condition or future results. The risks in our SEC filings are not the only risks we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition, and/or operating results. If any of the risks actually occur, our business, financial condition, and/or results of operations could be negatively affected.

 

If we fail to comply with the continued listing requirements of The Nasdaq Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.

 

On August 6, 2026, we received written notice from the Nasdaq Stock Market, LLC (“Nasdaq”) that we were not in compliance with Nasdaq Listing Rule 5550(a)(2), as the minimum bid price of our common stock had been below $1.00 per share for 30 consecutive business days. In accordance with Nasdaq Listing Rule 5810, we have a period of 180 calendar days, or until February 2, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of our common stock must meet or exceed $1.00 per share for at least 10 consecutive business days during this 180 calendar day period. In the event we do not regain compliance by February 2, 2027, we may be eligible for an additional 180 calendar day grace period if we meet the continued listing standards, with the exception of bid price, for The Nasdaq Capital Market, and we provide written notice to Nasdaq of our intention to cure the deficiency during the second compliance period. Although we may effect a reverse stock split of our issued and outstanding common stock in the future, there can be no assurance that such reverse stock split will enable us to regain compliance with the Nasdaq minimum bid price requirement.

  

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 5. OTHER INFORMATION

 

Rule 10b5-1 Trading Plans

 

During the fiscal quarter ended September 30, 2026, none of the Company’s directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”

 

38

 

 

ITEM 6. EXHIBITS

 

Exhibit No.   Description
31.1*   Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1**   Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2**   Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS*   Inline XBRL Instance Document
101.SCH*   Inline XBRL Taxonomy Extension Schema Document
101.CAL*   Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*   Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*   Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*   Cover Page Interactive Data File - the cover page from the Registrant’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 is formatted in Inline XBRL

 

* Filed herewith.
** Furnished herewith.

 

39

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  ROCKET ONE INC.
   
Date: November 13, 2026 By:  /s/ Robb Knie
    Robb Knie,
    Chief Executive Officer
    (Principal Executive Officer)
     
Date: November 13, 2026 By: /s/ David Briones
    David Briones,
    Chief Financial Officer
    (Principal Financial and Accounting Officer)

 

40